

BUKTI KORESPONDENSI
ARTIKEL JURNAL NASIONAL SINTA 2

Judul artikel: Bacterial Profile and Antibiotic Susceptibility Test among Diabetes Mellitus Patients with Gangrene in Surabaya

Jurnal : Journal of Vocational Health Studies, 7 (No. 3)

Author : Imro'atul Qona'ah, 'Aliyah Siti Sundari, Ratna Wahyuni, Dwi Wahyu Indriati

No	Perihal	Tanggal
1	Bukti pengiriman artikel	23 Januari 2023
2	Bukti penerimaan revisi I	8 Maret 2023
3	Bukti pengiriman revisi I	1 April 2023
4	Bukti penerimaan review II	21 Agustus 2023
5	Bukti pengiriman revisi II	22 Agustus 2023
6	Bukti penerimaan artikel	24 Agustus 2023

BUKTI KORESPONDENSI
ARTIKEL JURNAL NASIONAL SINTA 2

Judul artikel: Bacterial Profile and Antibiotic Susceptibility Test among Diabetes Mellitus Patients with Gangrene in Surabaya

Jurnal : Journal of Vocational Health Studies, 7 (No. 3)

Author : Imro'atul Qona'ah, 'Aliyah Siti Sundari, Ratna Wahyuni, Dwi Wahyu Indriati

No	Perihal	Tanggal
1	Bukti pengiriman artikel	23 Januari 2023

The screenshot shows the submission management interface for the Journal of Vocational Health Studies. The top navigation bar includes the journal name, a home icon, a notification bell, and a user profile icon. A breadcrumb trail shows '← Back to Submissions'. Below this, there are tabs for 'Submission', 'Review', 'Copyediting', and 'Production'. The 'Submission Files' section contains a table with the following data:

File ID	File Name	Date	Type
187034	(ENG) Template Research Report-imroatul.pdf	January 23, 2023	Article Text
187973	Author Statement-imroatul (3).pdf	December 23, 2022	Article Text
187974	CTA JVHS-imroatul.pdf	December 23, 2022	Article Text
189005	Penilaian sesi 1-29122022- Bacterial Profile and Antibiotic.docx	December 29, 2022	Article Text

A search bar is located at the top right of the file list, and a 'Download All Files' button is at the bottom right.




BUKTI KORESPONDENSI
ARTIKEL JURNAL NASIONAL SINTA 2

Judul artikel: Bacterial Profile and Antibiotic Susceptibility Test among Diabetes Mellitus Patients with Gangrene in Surabaya

Jurnal : Journal of Vocational Health Studies, 7 (No. 3)

Author : Imro'atul Qona'ah, 'Aliyah Siti Sundari, Ratna Wahyuni, Dwi Wahyu Indriati

No	Perihal	Tanggal
2	Bukti penerimaan revisi I	8 Maret 2023

 **Journal of Vocational Health Studies**  

[← Back to Submissions](#)

Revisions [Q Search](#) [Upload File](#)

No Files

Review Discussions [Add discussion](#)

Name	From	Last Reply	Replies	Closed
JVHS-Hasil Tinjau Naskah A dan B	dinyamalia 2023-03-08 12:02 PM	dwiwahyu 2023-04-01 09:28 AM	1	<input type="checkbox"/>
JVHS-Reminder	dinyamalia 2023-03-27 12:28 PM	-	0	<input type="checkbox"/>
JVHS-Result of Revision by Chief	dinyamalia 2023-08-21 02:04 PM	-	0	<input type="checkbox"/>

[https://e-journal.unair.ac.id/JVHS/\\$\\$\\$call\\$\\$\\$/tab/author-dashboard/author-dashboard-review-round-tab/fetch-review-round-info?submissionId=41535&stagelId=3&reviewRoundId=22753](https://e-journal.unair.ac.id/JVHS/$$$call$$$/tab/author-dashboard/author-dashboard-review-round-tab/fetch-review-round-info?submissionId=41535&stagelId=3&reviewRoundId=22753)

Journal of Vocational Health Sciences

← Back to Submissions

Participants

Dwi Wahyu Indriati, S.Si., Ph.D. (dwiwahyu)
Diny Amalia Putri (dinyamalia)

Messages

Note	From
Kepada Yth. Ibu Dwi Wahyu Indriati	dinyamalia 2023-03-08 12:02 PM
Melalui ini, kami memberitahukan hasil tinjau oleh Reviewer A dan B JVHS (terlampir) dan menyampaikan tambahan komentar	
Reviewer A:	
<ol style="list-style-type: none">1. Please kindly elaborate handling specimen methods, is it true Pus swab or wound bed swab?2. Use G capital in all Gram staining3. Please use the updated references4. Mohon diperbaiki sesuai saran	
Reviewer B:	

Journal of Vocational Health Sciences

← Back to Submissions

Reviewer B:

1. Naskah sudah komprehensif dan memberikan informasi yang penting. walaupun demikian penulis perlu melakukan sedikit perbaikan di penulisan, metode dan pembahasan.
2. naskah dengan komentar detail dari reviewer terlampir.

Kami menunggu hasil perbaikan naskah sampai Rabu, 22 Maret 2023

Hasil perbaikan artikel mohon dijadikan satu dan dapat diupload pada web JVHS dalam bentuk .doc

Terima kasih

- 📎 Hasil tinjau A-08032023-Bacterial Profile.docx
- 📎 Hasil tinjau B-10022023-Bacterial Profile and Antibiotic.docx



Hasil tinjau A:

1. Please kindly elaborate handling specimen methods, is it true Pus swab or wound bed swab?
2. Use G capital in all Gram staining
3. Please use the updated references
4. Mohon diperbaiki sesuai saran

Bacterial Profile and Antibiotic Susceptibility Test among Diabetes Mellitus Patients with Gangrene in Surabaya (English)

Profil Bakteri dan Uji Kerentanan Antibiotik pada pasien Diabetes Melitus dengan Gangren di Surabaya (Indonesian)

ABSTRACT

Background: Gangrene is a severe complication of damaged tissue that can occur in people with diabetes mellitus and putting them at risk for bacterial infection. Pus culture can show diabetic gangrene patients' infecting bacteria.

Purpose: This study aims to determine the prevalence of infection-causing bacteria and antibiotic sensitivity tests in diabetic gangrene patients at Haji Regional General Hospital, East Java Province, for January-December 2021.

Methods: The method used in this study is Observational Analytical Cross-Sectional, which is based on secondary data and is analyzed using the percentage formula and chi-square test.

Results: The data obtained from 39 patients revealed 29 (74.4%) positive patients for bacterial infection. The Gram-negative bacteria were found to be the cause of infection more frequently (72.41%) than the Gram-positive bacteria (27.59%). The prevalence of Gram-negative bacteria species most frequently from *Escherichia coli* (ESBL) 13.79% (4/29), *Klebsiella pneumoniae* 10.35% (3/29), *Proteus mirabilis* 10.35% (3/29). While the dominant Gram-positive bacteria a Methicillin-Resistant *Staphylococcus aureus* (MRSA) 10.35% (3/29). The antibiotic sensitivity test showed that Gram-negative group were susceptible Ertapenem, Meropenem, Amikacin, Gentamicin, Piperacillin Tazobactam while resistant to



Ampicillin and Cefazolin. The antibiotic sensitivity tests showed that the Gram-positive group were susceptible to Linezolid, Vancomycin and Tigecycline while resistant to Tetracycline and Ciprofloxacin.

Conclusion: *it is importance to screen the bacterial profile causing gangrene and their antibiotic susceptibility pattern in DM patients in order to give a proper treatment for DM patients*

Keywords: *antibiotic resistance, diabetes melitus, E. coli, gangrene, pus*

ABSTRAK

Latar Belakang: Gangren merupakan komplikasi serius berupa jaringan rusak yang dapat terjadi pada penderita diabetes melitus dan sangat berisiko mengalami infeksi bakteri. Pemeriksaan menggunakan kultur pus dapat menunjukkan bakteri penyebab infeksi pada penderita gangren diabetik.

Tujuan: Penelitian ini bertujuan untuk mengetahui prevalensi bakteri penyebab infeksi dan uji kepekaan antibiotik pada penderita gangren diabetik di Rumah Sakit Umum Daerah Haji Provinsi Jawa Timur periode Januari - Desember 2021.

Metode: Metode yang digunakan pada penelitian adalah *Observational Analytical Cross Sectional* dari data sekunder, yang dianalisis dengan rumus presentase dan *chi square*.

Hasil: Hasil data yang diperoleh dari total 39 pasien yaitu 29 (74,4%) pasien positif terinfeksi bakteri. Bakteri penyebab infeksi tertinggi oleh kelompok Gram negatif yaitu 72,41% (21/29), dan bakteri Gram positif yaitu 27,59 % (8/29). Prevalensi spesies bakteri Gram negatif yang dominan oleh *Escherichia coli* (ESBL) 13,79% (4/29), *Klebsiella pneumoniae* 10,35% (3/29), dan *Proteus mirabilis* 10,35% (3/29). Sedangkan pada Gram positif dominan oleh *Methicilin-Resistant Staphylococcus aureus* (MRSA) 10,35% (3/29). Uji kepekaan antibiotik yang diperoleh berdasarkan kelompok Gram negatif yang sensitif adalah *Ertapenem, Meropenem, Amikacin, Gentamicin, Piperacillin Tazobactam* serta resistan terhadap *Ampicillin* dan *Cefazoline*. Uji kepekaan antibiotik untuk kelompok Gram positif sensitif terhadap *Linezolid, Vancomycin* dan *Tigecycline*. Sedangkan antibiotik yang resistan yaitu *Tetracycline* dan *Ciprofloxacin*.

Kesimpulan: hasil dari penelitian ini menunjukkan perlunya skrining untuk melihat profil bakteri penyebab gangrene beserta pola kerentanannya terhadap antibiotik pada pasien DM sehingga dapat memberikan pengobatan yang tepat pada pasien DM.

Kata kunci: DM, *E. coli*, gangrene, pus, resistensi antibiotik



INTRODUCTION

Diabetes mellitus is a rapidly spreading health problem. In 2045, 700 million adults worldwide are predicted to have the disease (International Diabetes Federation (IDF), 2019). Diabetes patient commonly experience foot complications. Diabetes patients frequently experience foot problems, with foot ulcers being one of the more devastating effects. If diabetic foot infections (DFI) are not promptly and properly treated, these ulcers frequently get infected and can result in septic gangrene and amputation. Amputation is a possibility with diabetic foot ulcers (DFUs), a serious consequence of diabetes mellitus (Apelqvist *et al.*, 2011; Spreen *et al.*, 2016). Studies have indicated that diabetes persons are eight times more likely to experience a vascular lower limb amputation at or near the trans-metatarsal level than nondiabetic individuals under the age of 45 (Johannesson *et al.*, 2009).

The most common way to define diabetic foot infections is as an inflammatory reaction and tissue harm brought on by an interaction between the host and microbial pathogens (Williams *et al.*, 2004). Reduced peripheral circulation, inflammation, and infection have all been put out as potential causes of gangrene, though these theories have been contested (Gershater *et al.*, 2009; Schaper *et al.*, 2017). Although a few studies have described certain filamentous fungi and yeasts as the etiological agents of diabetic foot infections, the majority of infections in the diabetic foot are of aerobic and anaerobic bacterial origin, and in most cases polymicrobial (Bowler *et al.*, 2001; Johnson *et al.*, 1995).

Gram-positive bacteria like *Staphylococcus aureus* and *Enterococcus faecalis*, together with Gram-negative bacteria like *Escherichia coli* and *Pseudomonas aeruginosa*, were shown to be the most prevalent flora of diabetic foot infections, according to earlier investigations (Fejfarová *et al.*, 2002; Mantey *et al.*, 2000). With the advancement of diabetes epidemiology and modifications in the use of antimicrobial medications, the bacterial spectrum of diabetic foot infections has changed significantly in recent years (Chen *et al.*, 2017; Saltoglu *et al.*, 2018). It is crucial to concentrate on evaluating the risk factors of multi-drug resistant bacterial infections in order to find a more effective treatment because the increasingly severe form of prevention and treatment of diabetic foot ulcer infections is associated with a high rate of detection of multi-drug resistant bacteria (Agbi *et al.*, 2017; Belefquih *et al.*, 2016). Commonly in diabetic foot infection we can found Methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant *Enterococcus* (VRE), Enterobacteriaceae that produce ultra-broad spectrum - lactamases (ESBLs), such as *Escherichia coli* and *Klebsiella pneumoniae*, carbapenem-resistant Enterobacteriaceae, multidrug-resistant *Pseudomonas aeruginosa* (MDR-PA)(Yan *et al.*, 2022). Thus,



this study aims to listed bacterial profile causing gangrene (wet gangrene) among diabetic patient in Surabaya.

MATERIAL AND METHOD

Study site and population

A retrospective cross-sectional study was carried out from January to December 2021 at East Java Province Government Hospital, Surabaya Indonesia. The ethical clearance was obtained from ethical committee of this hospital. This hospital is a government building which also act as a teaching facility. With at least 200 beds, this hospital is classified as a type B hospital in Indonesia, and patients with National Health Insurance coverage are welcome to receive care there. Additionally, several district hospitals in Surabaya and the province of East Java used this hospital as their model facility. This hospital offers seventeen different specialties, including pediatrics, anesthesia, dental specialties, internal medicine, radiology, and others.

Data and specimen collection

Pus sample was collected from 39 DM patients with gangrene. Pus samples were collected using swab methods. Samples were then processed to the Microbiology Laboratory Department.

Culture and identification techniques

Swab samples were inoculated onto plates of 5% blood agar, MacConkey agar (Oxoid Ltd, Basingstoke, UK). Incubation was carried out overnight under aerobic conditions at 37°C. The VITEK® 2 device (bioMérieux, USA) was utilized to identify the isolates using conventional bacteriological techniques and biochemical testing. These tests included those for motility, catalase, oxidase, urease, indole, citrate utilization, gas production, H₂S production, and sugar fermentation. In order to preserve pure cultures, subcultures of many distinct colonies were carried out in cultures that were yielding more than one bacterium.

Antimicrobial Susceptibility Testing

Antibiotics sensitivity testing was performed on sensitivity test agar using VITEK® 2 apparatus (bioMérieux, USA) in accordance with National Committee for Clinical Laboratory Standards. Antibiotic class penicillin (ampicillin); penicillin and beta lactamase inhibitor (ampicillin sulbactam, piperacillin tazobactam), class cephalosporins (cefazolin, ceftazidime, ceftriaxone, cefepime), class carbapenems



(ertapenem, meropenem), class beta lactamase inhibitor (aztreonam), class nitrofurantoin (nitrofurantoin), class aminoglycosides (amikacin, gentamicin), class fluoroquinolones (ciprofloxacin), and class glycyline (tigecycline) were used for gram-negative bacteria. Antibiotic class penicillin (ampicillin, oxacillin, benzylpenicillin); class aminoglycosides (gentamicin); class glycyline (tigecycline); class sulfonamides (trimethoprim/sulfamethoxazole); class tetracycline (tetracyclin); class fluoroquinolones (moxifloxacin, levofloxacin, ciprofloxacin); class lincomycin (clindamycin); class oxazolidinone (linezolid), class glycopeptide (vancomycin), class macrolides (erythromycin); class nitrofurantoin (nitrofurantoin) and class rifampisin (rifampisin) were used for gram-positive bacteria. Antibiotics were classified using the 2019 WHO AwaRe classification of antibiotics for evaluation and monitoring of use. Results were classified as either resistant (R) or sensitive (S) to the tested antibiotics using the interpretive guidelines given by the Clinical and Laboratory Standards Institute (CLSI). The tested antibiotics can still be utilized for therapy because of the sensitive results. Since there are bacterial resistances to the antibiotics being tested in this investigation, the readings utilizing this technique (S or R type) reveal this. Multi-Drug Resistance was defined as bacterial isolates that were resistant to three or more antimicrobials from various structural classes (MDR).

Statistical analysis

The results obtained in this study are number of bacteria based on species identification and results of antibiotic susceptibility tests. Categorical data is presented in the form of frequency and percentage.

RESULT

Our results show that among 39 DM patient with gangrene, 19 patients (48.3%) were male and 20 patients (51.7%) were female. Among those patients, 76.9% (30/39 patients) were included in productive age category (45-59 years), while 7.7% (3/39 patients) were categorized as young adult or 25-44 years old and 15.4% (6/39 patients) were included in elderly category or above 65 years old (Table 1). Pus culture showed microbial growth in 29 patients (74.4%) while 10 patients (25.6%) showed no microbial growth.

Table 1. Demographic information of DM patient with gangrene

Sample	Number of patients (Percentage)
--------	---------------------------------



Gender	
Male	19 (48.7)
Female	20 (51.3)
Age (years)	
25-44	3 (7.7)
45-59	30 (76.9)
60-75	6 (15.4)

Pus culture showed the appearance of microbial drug resistance organisms (MDRO) which is *Escherichia coli*- extended spectrum beta lactamase (ESBL) in 4 patients (13.8%). Our result also found another MDRO which is methicillin resistant *Staphylococcus aureus* (MRSA) in 3 patients (10.4%) (Table 2). In comparison the appearance of gram-negative bacteria is dominant compare to gram-positive bacteria (72.4% compare to 27.6%). In case of gram negative, the study showed Enterobacteriaceae were seen enormously causing gangrene in DM patients such as *Klebsiella pneumoniae* (3 patients, 10.4%), *Proteus mirabilis* (3 patients, 10.4%).

Table 2. Bacterial profile causing gangrene among DM patient from pus sample

No	Bacteria	Number (Percentage)
Gram negative bacteria		
1	<i>Escherichia coli (ESBL)</i>	4 (13.8)
2	<i>Klebsiella pneumoniae</i>	3 (10.4)
3	<i>Proteus mirabilis</i>	3 (10.4)
4	<i>Citrobacter freundii</i>	2 (6.9)
5	<i>Citrobacter koseri</i>	2 (6.9)
6	<i>Enterobacter cloacae</i>	2 (6.9)
7	<i>Enterobacter aerogenes</i>	1 (3.5)
8	<i>Morganella morganii</i>	1 (3.5)
9	<i>Proteus hauseri</i>	1 (3.5)
10	<i>Shigella sp</i>	1 (3.5)
11	<i>Pseudomonas putida</i>	1 (3.5)
Gram positive bacteria		
12	<i>Methicillin Resistant Staphylococcus aureus (MRSA)</i>	3 (10.4)



n=1(%)																
<i>Proteus hauseri</i> n=1(%)	1 (100)	1 (100)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Morganella morganii</i> n=1(%)	1 (100)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Shigella sp</i> n=1(%)	1 (100)	1 (100)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)	1 (100)	1 (100)	0 (0)
<i>Pseudomonas putida</i> n=1(%)	0 (0)	0 (0)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	0 (0)	1 (100)	1 (100)	1 (100)	0 (0)	1 (100)	1 (100)

AMP, Ampicillin; SAM, Ampicillin Sulbactam; TZP, Piperacillin Tazobactam; KZ, Cefazolin; CAZ, Ceftazidime; CRO, Ceftriaxone; FEP, Cefepim; ATM, Azteronam; ERTA, Ertapenem; MEM, Meropenem; AK, Amikacin; GN, Gentamicin; CIP, Ciprofloxacin; F, Nitrofurantoin; SXT, Trimethoprim/sulfamethoxazole; TGC, Tigecycline.

Table 4. Antibiotic Susceptibility Results from Gram Negative Bacteria Causing Gangrene among DM patient

Antibiotics	AMP	SAM	TZP	KZ	CAZ	CRO	FEP	ATM	ERT A	MEM	AK	GN	CIP	F	SXT	TGC
<i>Escherichia coli</i> (ESBL) n=4 (%)	0 (0)	0 (0)	3 (75)	0 (0)	2 (50)	0 (0)	3 (75)	1 (25)	4 (100)	4 (100)	4 (100)	3 (75)	0 (0)	4 (100)	1 (25)	4 (100)
<i>Klebsiella pneumoniae</i> n=3 (%)	3 (100)	1 (33)	3 (100)	0 (0)	1 (33)	1 (33)	1 (33)	1 (33)	3 (100)	3 (100)	3 (100)	1 (33)	0 (0)	0 (0)	2 (67)	0 (0)
<i>Proteus mirabilis</i> n=3 (%)	1 (33)	2 (67)	2 (67)	0 (0)	2 (67)	2 (67)	2 (67)	1 (33)	1 (33)	3 (100)	3 (100)	2 (67)	2 (67)	0 (0)	1 (33)	0 (0)
<i>Citrobacter freundii</i> n=2 (%)	0 (0)	0 (0)	1 (50)	0 (0)	1 (50)	1 (50)	2 (100)	0 (0)	2 (100)	2 (100)	2 (100)	1 (50)	1 (50)	1 (50)	1 (50)	2 (100)
<i>Citrobacter koseri</i> n=2 (%)	0 (0)	1 (50)	2 (100)	0 (0)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	0 (0)	2 (100)	1 (50)
<i>Enterobacter cloaee</i> n=2 (%)	0 (0)	0 (0)	1 (50)	0 (0)	1 (50)	1 (50)	2 (100)	1 (50)	1 (50)	2 (100)	2 (100)	2 (100)	0 (0)	0 (0)	1 (50)	1 (50)
<i>Enterobacter aerogenes</i> n=1(%)	0 (0)	0 (0)	1 (100)	0 (0)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	0 (0)	1 (100)	1 (100)
<i>Proteus hauseri</i> n=1(%)	0 (0)	0 (0)	1 (100)	0 (0)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	0 (0)	1 (100)	0 (0)
<i>Morganella morganii</i> n=1(%)	0 (0)	0 (0)	1 (100)	0 (0)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	0 (0)	1 (100)	0 (0)
<i>Shigella sp</i> n=1(%)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)	1 (100)	1 (100)	1 (100)	0 (0)	1 (100)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Pseudomonas putida</i> n=1(%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

AMP, Ampicillin; SAM, Ampicillin Sulbactam; TZP, Piperacillin Tazobactam; KZ, Cefazolin; CAZ, Ceftazidime; CRO, Ceftriaxone; FEP, Cefepim; ATM, Azteronam; ERTA, Ertapenem; MEM, Meropenem; AK, Amikacin; GN, Gentamicin; CIP, Ciprofloxacin; F, Nitrofurantoin; SXT, Trimethoprim/sulfamethoxazole; TGC, Tigecycline.

The results of antibiotic resistance test of gram-positive bacteria showed resistant to tetracyclin and ciprofloxacin. Apart from beta lactam antibiotics, MRSA showed resistance to aminoglycosides class



(gentamicin), tetracycline, fluoroquinolone class (moxifloxacin, levofloxacin, ciprofloxacin), lincomycin class (clindamycin) and macrolides class (clindamycin) (Table 5). MRSA showed susceptibility to tigecycline, linezolid, vancomycin and furantoin. Others gram positive bacteria showed susceptible to linezolid, vancomycin, tigecycline, ampicillin (Table 6). While other gram-positive bacteria showed resistance to tetracycline and showed susceptibility to linezolid and vancomycin (Table 5 and 6).

Table 5. Antibiotic Resistance Results from Gram Positive Bacteria Causing Gangrene among DM patients

Antibiotics	AMP	OXA	BEN	GN	TGC	SXT	TE	MXF	LEV	CIP	CC	LZD	VA	E	F	Rif
<i>Methicillin Resistant Staphylococcus aureus</i> (MRSA) n=3 (%)	0 (0)	3 (100)	0 (0)	3 (100)	0 (0)	1 (33)	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)	0 (0)	0 (0)	3 (100)	0 (0)	2 (67)
<i>Enterococcus faecalis</i> n=2 (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (50)	0 (0)	0 (0)
<i>Enterococcus avium</i> n=1 (%)	0 (0)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)	0 (0)
<i>Staphylococcus haemolyticus</i> n=1 (%)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)	0 (0)	1 (100)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Staphylococcus hominis</i> n=1 (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

AMP, Ampicillin; OXA, Oxacillin; BEN, Benzylpenicillin; GN, Gentamicin; TGC, Tigecycline; SXT, Trimethoprim Sulfamethoxazole; TE, Tetracycline; MXF, Moxifloxacin; LEV, Levofloxacin; CIP, Ciprofloxacin; CC, Clindamycin; LZD, Linezolid; VA, Vancomycin; E, Erythromycin; F, Nitrofurantoin; Rif, Rifampicin.

Antibiotics	AMP	OXA	BEN	GN	TGC	SXT	TE	MXF	LEV	CIP	CC	LZD	VA	E	F	Rif
<i>Methicillin Resistant Staphylococcus aureus</i> (MRSA) n=3 (%)	0 (0)	0 (0)	0 (0)	0 (0)	3 (100)	1 (33)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (100)	3 (100)	0 (0)	3 (100)	1 (33)
<i>Enterococcus faecalis</i> n=2 (%)	2 (100)	0 (0)	0 (0)	0 (0)	2 (100)	0 (0)	0 (0)	0 (0)	2 (100)	2 (100)	0 (0)	2 (100)	2 (100)	0 (0)	1 (50)	0 (0)
<i>Enterococcus avium</i> n=1 (%)	1 (100)	0 (0)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)	1 (100)	0 (0)	0 (0)	0 (0)
<i>Staphylococcus haemolyticus</i> n=1 (%)	0 (0)	0 (0)	1 (100)	1 (100)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)	1 (100)	1 (100)	1 (100)	0 (0)	1 (100)
<i>Staphylococcus hominis</i> n=1 (%)	0 (0)	0 (0)	0 (0)	1 (100)	0 (0)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	0 (0)	1 (100)	0 (0)	1 (100)	1 (100)	0 (0)

Table 6. Antibiotic Susceptibility Results from Gram Positive Bacteria Causing Gangrene among DM patients
Sulfamethoxazole; TE, Tetracycline; MXF, Moxifloxacin; LEV, Levofloxacin; CIP, Ciprofloxacin; CC, Clindamycin; LZD, Linezolid; VA, Vancomycin; E, Erythromycin; F, Nitrofurantoin; Rif, Rifampicin.



DISCUSSION

Demographic information of DM patient reveals that in term of gender there is no different in probability of DM patient to develop gangrene. While in term of age, DM patients in group of 45-59 years old showing high probability of developing gangrene. This study also in accordance with other studies by Tong et al in 2020 that stated DFU (diabetic foot ulcers) is common in middle-aged patients. Also study conducted in Saudi Arabia that showed > 45 years of age can poses a threat for developing DFU (Al-Rubeaan *et al.*, 2015; AlSadrah, 2019). Our study demonstrated that middle-aged patients with DFUs had worse glycemic control, made worse lifestyle decisions like smoking and drinking, had more severe ulcers, and were more likely to have microangiopathy problems. However, these individuals subsequently recovered more quickly and were at a lower risk of death and significant amputation (Tong *et al.*, 2020).

Our result showed that bacterial found in pus culture dominated by gram negative bacteria. With *E. coli* ESBL, MRSA, *Klebsiella pneumoniae*, *Proteus mirabilis* being the most common bacteria causing gangrene. Gram-negative rods were mostly found in patients with chronic wounds that had already been treated. Beginning in the late 1970s, studies showed that aerobic Gram-positive cocci, particularly *Staphylococcus aureus*, were the most common pathogens in DFIs, frequently as monomicrobial infections. Aerobic DFIs brought on by multidrug-resistant organisms, including extended-spectrum beta-lactamase-producing Gram-negative rods (Varaiya *et al.*, 2008) or methicillin-resistant *S. aureus* (MRSA), have become a significant issue in recent years. The choice of an agent active against that isolate is undoubtedly necessary in the event of an infection with an antibiotic-resistant bacterium, but therapeutic management should remain unchanged (Uçkay *et al.*, 2012).

When we adding the number of *E. coli* ESBL and MRSA we found that 24 % cases were causing by Multidrug-resistant bacterial infection. Another factor contributing to the appearance of MDRO in other study by Dubsky et al ini 2013 were because of long term poor glucose control in DM patient (Dubský *et al.*, 2013). By reducing the therapeutic efficacy of antibiotic therapy, MDRO infection in diabetic foot ulcers makes treatment more difficult and may even result in fatalities or amputations (Agbi et al., 2017; Yan et al., 2022). The risk factors of drug-resistant negative bacilli in patients should be assessed in the development of the initial anti-infective treatment regimen in clinical practice due to the increased resistance rate of *E. coli* ESBL among gram-negative bacteria. Another study also noted that the



appearance of MDRO might be related to the patients with serious illness admitted to our hospital as a tertiary care hospital and the more complex history of antibacterial drug use (Yan *et al.*, 2022).

Systemic antibiotic therapy is required for patients with poor systemic resistance, which typically coexists with bacteremia or sepsis. As a result, it's crucial to perform a thorough evaluation of each patient with diabetic foot ulcers, keep an eye on the severity of the infection and any changes in the pathogenic bacteria, and administer anti-infective therapy in a consistent manner (Tang, 2019). The majority of diabetic foot infections (DFIs) require systemic antibiotic therapy, with empirical selection being the norm at first. Even though there are numerous antibiotics available, it is unclear which one is best for treating DFIs. Antibiotic susceptibility that gram negative bacteria (wild type and MDRO) showed susceptibility to meropenem class, aminoglikosida class and beta lactamase inhibitor antibiotic. While for gram negative bacteria without MDRO, cephalosporin, beta lactamase antibiotics still susceptible in this study. In case of gram-positive bacteria, it showed susceptibility to tigecycline, linezolid, vancomycin. Other studies suggested that ertapenem with or without vancomycin also tigecycline can be used to treat DFI infection (Selva Olid *et al.*, 2015). Study by Du et al in 2022 also showed that gram positive bacteria were susceptible to linezolid, vancomycin, teicoplanin (Du *et al.*, 2022).

CONSLUSION

The gangrene or diabetic foot infection occur in the middle age group (45-59 years) old accounted for 76.9%. Pus culture showed *E. coli* ESBL, MRSA, *Klebsiella pneumoniae*, *Proteus mirabilis* as the dominant bacteria found. Gram negative bacteria were highly sensitive to meropenem class (ertapenem and meropenem, aminoglikosida class (amikacin, gentamicin) and tigecycline class of antibiotics *Ertapenem*, meropenem, amikacin, gentamicin, piperacillin tazobactam. While gram positive bacteria were highly sensitive to tigecycline, linezolid and vancomycin.

ACKNOWLEDGMENTS

The authors wanted to thank East Java Province Government Hospital for giving us the provided research materials. We also wanted to thanked all member of Microbiology department in that hospital for their guidance in helping collecting secondary data. The authors state there is no conflict of interest with the parties involved in this study.



REFERENCES

1. Agbi, K.E., Carvalho, M., Phan, H. and Tuma, C. 2017. Case Report: Diabetic Foot Ulcer Infection Treated with Topical Compounded Medications. *International Journal of Pharmaceutical Compounding*. Vol. 21 (1). Pp. 22–27.
2. Al-Rubeaan, K., Al Derwish, M., Ouizi, S., Youssef, A.M., Subhani, S.N., Ibrahim, H.M. and Alamri, B.N. 2015. Diabetic foot complications and their risk factors from a large retrospective cohort study. *PloS One*. Vol. 10 (5). Pp. e0124446.
3. ALSadrah, S.A. 2019. Impaired quality of life and diabetic foot disease in Saudi patients with type 2 diabetes: A cross-sectional analysis. *SAGE Open Medicine Ltd*. Vol. 7. Pp. 2050312119832092.
4. Apelqvist, J., Elgzyri, T., Larsson, J., Löndahl, M., Nyberg, P. and Thörne, J. 2011. Factors related to outcome of neuroischemic/ischemic foot ulcer in diabetic patients. *Journal of Vascular Surgery*. Vol. 53 (6) Pp. 1582–8.e2.
5. Belefquih, B., Frikh, M., Benlahlou, Y., Maleh, A., Jadid, L., Bssaibis, F., Ghazouani, M., et al. 2016. Diabetic Foot Infection in Morocco: Microbiological Profile. *Wounds : A Compendium of Clinical Research and Practice*. Vol. 28 (3). Pp. 89–98.
6. Bowler, P.G., Duerden, B.I. and Armstrong, D.G. 2001. Wound microbiology and associated approaches to wound management. *Clinical Microbiology Reviews*. Vol. 14 (2). Pp. 244–269.
7. Chen, Y., Ding, H., Wu, H. and Chen, H.-L. 2017. The Relationship Between Osteomyelitis Complication and Drug-Resistant Infection Risk in Diabetic Foot Ulcer: A Meta-analysis. *The International Journal of Lower Extremity Wounds*. Vol. 16 (3). Pp. 183–190.
8. Du, F., Ma, J., Gong, H., Bista, R., Zha, P., Ren, Y., Gao, Y., et al. 2022. Microbial Infection and Antibiotic Susceptibility of Diabetic Foot Ulcer in China: Literature Review. *Frontiers in Endocrinology*. Vol. 13(May). Pp. 1–9.
9. Dubský, M., Jirkovská, A., Bem, R., Fejfarová, V., Skibová, J., Schaper, N.C. and Lipsky, B.A. 2013. Risk factors for recurrence of diabetic foot ulcers: prospective follow-up analysis in the Eurodiale subgroup. *International Wound Journal*. Vol. 10 (5). Pp. 555–561.
10. Fejfarová, V., Jirkovská, A., Skibová, J. and Petkov, V. 2002. Pathogen resistance and other risk factors in the frequency of lower limb amputations in patients with the diabetic foot syndrome. *Vnitřní lékařství*. Vol. 48 (4). Pp. 302–306.
11. Gershater, M.A., Löndahl, M., Nyberg, P., Larsson, J., Thörne, J., Eneroth, M. and Apelqvist, J. 2009. Complexity of factors related to outcome of neuropathic and neuroischaemic/ischaemic diabetic foot



- ulcers: a cohort study. *Diabetologia*. Vol. 52 (3). Pp. 398–407.
12. International Diabetes Federation (IDF). 2019. “IDF Diabetes Atlas”, 9th Edn. Available from: https://diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf. Access from December 12, 2022.
 13. Johannesson, A., Larsson, G.-U., Ramstrand, N., Turkiewicz, A., Wiréhn, A.-B. and Atroshi, I. 2009. Incidence of lower-limb amputation in the diabetic and nondiabetic general population: a 10-year population-based cohort study of initial unilateral and contralateral amputations and reamputations. *Diabetes Care*. Vol. 32 (2). Pp. 275–280.
 14. Johnson, S., Lebahn, F., Peterson, L.R. and Gerding, D.N. 1995. Use of an anaerobic collection and transport swab device to recover anaerobic bacteria from infected foot ulcers in diabetics. *Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America*. Vol. 20 (Suppl 2). Pp. S289-90.
 15. Mantey, I., Hill, R.L., Foster, A. V, Wilson, S., Wade, J.J. and Edmonds, M.E. 2000. Infection of foot ulcers with *Staphylococcus aureus* associated with increased mortality in diabetic patients. *Communicable Disease and Public Health*. Vol. 3 (4). Pp. 288–290.
 16. Saltoglu, N., Ergonul, O., Tulek, N., Yemisen, M., Kadanali, A., Karagoz, G., Batirel, A., et al. 2018. Influence of multidrug resistant organisms on the outcome of diabetic foot infection. *International Journal of Infectious Diseases*. Vol. 70, Pp. 10–14.
 17. Schaper, N.C., Van Netten, J.J., Apelqvist, J., Lipsky, B.A. and Bakker, K. 2017. Prevention and management of foot problems in diabetes: A Summary Guidance for Daily Practice 2015, based on the IWGDF guidance documents. *Diabetes Research and Clinical Practice*. Vol. 124. Pp. 84–92.
 18. Selva Olid, A., Solà, I., Barajas-Nava, L.A., Gianneo, O.D., Bonfill Cosp, X. and Lipsky, B.A. 2015. Systemic antibiotics for treating diabetic foot infections. *The Cochrane Database of Systematic Reviews*. Vol. 2015 (9). Pp. CD009061.
 19. Spreen, M.I., Gremmels, H., Teraa, M., Sprengers, R.W., Verhaar, M.C., Stadius van Eps, R.G., de Vries, J.-P.P.M., et al. 2016. Diabetes Is Associated With Decreased Limb Survival in Patients With Critical Limb Ischemia: Pooled Data From Two Randomized Controlled Trials. *Diabetes Care*. Vol. 39 (11). Pp. 2058–2064.
 20. Tang, Z.Y. 2019. The comprehension to the part of diabetic foot infection in Chinese guideline on prevention and management of diabetic foot (2019 edition). *World Clini Drugs*. Vol. 40 (9). Pp. 599–



602.

21. Tong, T., Yang, C., Tian, W., Liu, Z., Liu, B., Cheng, J., Cheng, Q., et al. 2020. Phenotypes and outcomes in middle-aged patients with diabetic foot ulcers: A retrospective cohort study. *Journal of Foot and Ankle Research*. Vol. 13 (1). Pp. 1–8.
22. Uçkay, I., Lübbecke, A., Harbarth, S., Emonet, S., Tovmirzaeva, L., Agostinho, A., Longtin, Y., et al. 2012. Low risk despite high endemicity of methicillin-resistant *Staphylococcus aureus* infections following elective total joint arthroplasty: A 12-year experience. *Annals of Medicine*. Vol. 44 (4). Pp. 360–368.
23. Varaiya, A., Dogra, J., Kulkarni, M. and Bhalekar, P. 2008. Extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in diabetic foot infections. *Indian Journal of Pathology and Microbiology*. Vol. 51 (3). Pp. 370–372.
24. Williams, D.T., Hilton, J.R. and Harding, K.G. 2004. Diagnosing foot infection in diabetes. *Clinical Infectious Diseases*. Vol. 39 (Suppl 2). Pp. S83-6.
25. Yan, X., Song, J.-F., Zhang, L. and Li, X. 2022. Analysis of risk factors for multidrug-resistant organisms in diabetic foot infection. *BMC Endocrine Disorders*. Vol. 22 (1). Pp. 46.



Bacterial Profile and Antibiotic Susceptibility Test among Diabetes Mellitus Patients with Gangrene in Surabaya (English)

Profil Bakteri dan Uji Kerentanan Antibiotik pada pasien Diabetes Melitus dengan Gangren di Surabaya (Indonesian)

ABSTRACT

Background: Gangrene is a severe complication of damaged tissue that can occur in people with diabetes mellitus and putting them at risk for bacterial infection. Pus culture can show diabetic gangrene patients' infecting bacteria.

Purpose: This study aims to determine the prevalence of infection-causing bacteria and antibiotic sensitivity tests in diabetic gangrene patients at Haji Regional General Hospital, East Java Province, for January-December 2021.

Methods: The method used in this study is Observational Analytical Cross-Sectional, which is based on secondary data and is analyzed using the percentage formula and chi-square test.

Results: The data obtained from 39 patients revealed 29 (74.4%) positive patients for bacterial infection. The Gram-negative bacteria were found to be the cause of infection more frequently (72.41%) than the Gram-positive bacteria (27.59%). The prevalence of Gram-negative bacteria species most frequently from *Escherichia coli* (ESBL) 13.79% (4/29), *Klebsiella pneumoniae* 10.35% (3/29), *Proteus mirabilis* 10.35% (3/29). While the dominant Gram-positive bacteria a Methicillin-Resistant *Staphylococcus aureus* (MRSA) 10.35% (3/29). The antibiotic sensitivity test showed that Gram-negative group were susceptible Ertapenem, Meropenem, Amikacin, Gentamicin, Piperacillin Tazobactam while resistant to Ampicillin and Cefazolin. The antibiotic sensitivity tests showed that the Gram-positive group were susceptible to Linezolid, Vancomycin and Tigecycline while resistant to Tetracycline and Ciprofloxacin.

Conclusion: it is importance to screen the bacterial profile causing gangrene and their antibiotic susceptibility pattern in DM patients in order to give a proper treatment for DM patients

Keywords: antibiotic resistance, diabetes melitus, *E. coli*, gangrene, pus



ABSTRAK

Latar Belakang: Gangren merupakan komplikasi serius berupa jaringan rusak yang dapat terjadi pada penderita diabetes melitus dan sangat berisiko mengalami infeksi bakteri. Pemeriksaan menggunakan kultur pus dapat menunjukkan bakteri penyebab infeksi pada penderita gangren diabetik.

Tujuan: Penelitian ini bertujuan untuk mengetahui prevalensi bakteri penyebab infeksi dan uji kepekaan antibiotik pada penderita gangren diabetik di Rumah Sakit Umum Daerah Haji Provinsi Jawa Timur periode Januari - Desember 2021.

Metode: Metode yang digunakan pada penelitian adalah *Observational Analytical Cross Sectional* dari data sekunder, yang dianalisis dengan rumus presentase dan *chi square*.

Hasil: Hasil data yang diperoleh dari total 39 pasien yaitu 29 (74,4%) pasien positif terinfeksi bakteri. Bakteri penyebab infeksi tertinggi oleh kelompok Gram negatif yaitu 72,41% (21/29), dan bakteri Gram positif yaitu 27,59 % (8/29). Prevalensi spesies bakteri Gram negatif yang dominan oleh *Escherichia coli* (ESBL) 13,79% (4/29), *Klebsiella pneumoniae* 10,35% (3/29), dan *Proteus mirabilis* 10,35% (3/29). Sedangkan pada Gram positif dominan oleh *Methicilin-Resistant Staphylococcus aureus* (MRSA) 10,35% (3/29). Uji kepekaan antibiotik yang diperoleh berdasarkan kelompok Gram negatif yang sensitif adalah *Ertapenem*, *Meropenem*, *Amikacin*, *Gentamicin*, *Piperacillin Tazobactam* serta resistan terhadap *Ampicillin* dan *Cefazoline*. Uji kepekaan antibiotik untuk kelompok Gram positif sensitif terhadap *Linezolid*, *Vancomycin* dan *Tigecycline*. Sedangkan antibiotik yang resistan yaitu *Tetracycline* dan *Ciprofloxacin*.

Kesimpulan: hasil dari penelitian ini menunjukkan perlunya skrining untuk melihat profil bakteri penyebab gangrene beserta pola kerentanannya terhadap antibiotic pada pasien DM sehingga dapat memberikan pengobatan yang tepat pada pasien DM.

Kata kunci: DM, *E. coli*, gangrene, pus, resistensi antibiotik

INTRODUCTION

Diabetes mellitus is a rapidly spreading health problem. In 2045, 700 million adults worldwide are predicted to have the disease (International Diabetes Federation (IDF), 2019). Diabetes patient commonly experience foot complications. Diabetes patients frequently experience foot problems, with foot ulcers being one of the more devastating effects. If diabetic foot infections (DFI) are not promptly and properly treated, these ulcers frequently get infected and can result in septic gangrene and amputation. Amputation



is a possibility with diabetic foot ulcers (DFUs), a serious consequence of diabetes mellitus (Apelqvist *et al.*, 2011; Spreen *et al.*, 2016). Studies have indicated that diabetes persons are eight times more likely to experience a vascular lower limb amputation at or near the trans-metatarsal level than nondiabetic individuals under the age of 45 (Johannesson *et al.*, 2009).

The most common way to define diabetic foot infections is as an inflammatory reaction and tissue harm brought on by an interaction between the host and microbial pathogens (Williams *et al.*, 2004). Reduced peripheral circulation, inflammation, and infection have all been put out as potential causes of gangrene, though these theories have been contested (Gershater *et al.*, 2009; Schaper *et al.*, 2017). Although a few studies have described certain filamentous fungi and yeasts as the etiological agents of diabetic foot infections, the majority of infections in the diabetic foot are of aerobic and anaerobic bacterial origin, and in most cases polymicrobial (Bowler *et al.*, 2001; Johnson *et al.*, 1995).

Gram-positive bacteria like *Staphylococcus aureus* and *Enterococcus faecalis*, together with Gram-negative bacteria like *Escherichia coli* and *Pseudomonas aeruginosa*, were shown to be the most prevalent flora of diabetic foot infections, according to earlier investigations (Fejfarová *et al.*, 2002; Mantey *et al.*, 2000). With the advancement of diabetes epidemiology and modifications in the use of antimicrobial medications, the bacterial spectrum of diabetic foot infections has changed significantly in recent years (Chen *et al.*, 2017; Saltoglu *et al.*, 2018). It is crucial to concentrate on evaluating the risk factors of multi-drug resistant bacterial infections in order to find a more effective treatment because the increasingly severe form of prevention and treatment of diabetic foot ulcer infections is associated with a high rate of detection of multi-drug resistant bacteria (Agbi *et al.*, 2017; Belefquih *et al.*, 2016). Commonly in diabetic foot infection we can found Methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant *Enterococcus* (VRE), Enterobacteriaceae that produce ultra-broad spectrum - lactamases (ESBLs), such as *Escherichia coli* and *Klebsiella pneumoniae*, carbapenem-resistant Enterobacteriaceae, multidrug-resistant *Pseudomonas aeruginosa* (MDR-PA)(Yan *et al.*, 2022). Thus, this study aims to listed bacterial profile causing gangrene (wet gangrene) among diabetic patient in Surabaya.

MATERIAL AND METHOD

Study site and population

A retrospective cross-sectional study was carried out from January to December 2021 at East Java Province Government Hospital, Surabaya Indonesia. The ethical clearance was obtained from ethical



committee of this hospital. This hospital is a government building which also act as a teaching facility. With at least 200 beds, this hospital is classified as a type B hospital in Indonesia, and patients with National Health Insurance coverage are welcome to receive care there. Additionally, several district hospitals in Surabaya and the province of East Java used this hospital as their model facility. This hospital offers seventeen different specialties, including pediatrics, anesthesia, dental specialties, internal medicine, radiology, and others.

Data and specimen collection

Pus sample was collected from 39 DM patients with gangrene. Pus samples were collected using swab methods. Samples were then processed to the Microbiology Laboratory Department.

Culture and identification techniques

Swab samples were inoculated onto plates of 5% blood agar, MacConkey agar (Oxoid Ltd, Basingstoke, UK). Incubation was carried out overnight under aerobic conditions at 37°C. The VITEK® 2 device (bioMérieux, USA) was utilized to identify the isolates using conventional bacteriological techniques and biochemical testing. These tests included those for motility, catalase, oxidase, urease, indole, citrate utilization, gas production, H₂S production, and sugar fermentation. In order to preserve pure cultures, subcultures of many distinct colonies were carried out in cultures that were yielding more than one bacterium.

Antimicrobial Susceptibility Testing

Antibiotics sensitivity testing was performed on sensitivity test agar using VITEK® 2 apparatus (bioMérieux, USA) in accordance with National Committee for Clinical Laboratory Standards. Antibiotic class penicillin (ampicillin); penicillin and beta lactamase inhibitor (ampicillin sulbactam, piperacillin tazobactam), class cephalosporins (cefazolin, ceftazidime, ceftriaxone, cefepime), class carbapenems (ertapenem, meropenem), class beta lactamase inhibitor (aztreonam), class nitrofurantoin (nitrofurantoin), class aminoglycosides (amikacin, gentamicin), class fluoroquinolones (ciprofloxacin), and class glycyline (tigecycline) were used for gram-negative bacteria. Antibiotic class penicillin (ampicillin, oxacillin, benzylpenicillin); class aminoglycosides (gentamicin); class glycyline (tigecycline); class sulfonamides (trimethoprim/sulfamethoxazole); class tetracycline (tetracyclin); class fluoroquinolones (moxifloxacin, levofloxacin, ciprofloxacin); class lincomycin (clindamycin); class oxazolidinone (linezolid), class



glycopeptide (vancomycin), class macrolides (erythromycin); class nitrofurantoin (nitrofurantoin) and class rifampisin (rifampisin) were used for gram-positive bacteria. Antibiotics were classified using the 2019 WHO AwaRe ([Access, Watch, Reserve](#)) classification of antibiotics for evaluation and monitoring of use. Results were classified as either resistant (R) or sensitive (S) to the tested antibiotics using the interpretive guidelines given by the Clinical and Laboratory Standards Institute (CLSI). The tested antibiotics can still be utilized for therapy because of the sensitive results. Since there are bacterial resistances to the antibiotics being tested in this investigation, the readings utilizing this technique (S or R type) reveal this. Multi-Drug Resistance was defined as bacterial isolates that were resistant to three or more antimicrobials from various structural classes (MDR).

Formatted[AN]: Font: (Default)Times New Roman, 12 pt,
Not Bold

Statistical analysis

The results obtained in this study are number of bacteria based on species identification and results of antibiotic susceptibility tests. Categorical data is presented in the form of frequency and percentage.

RESULT

Our results show that among 39 DM patient with gangrene, 19 patients (48.3%) were male and 20 patients (51.7%) were female. Among those patients, 76.9% (30/39 patients) were included in productive age category (45-59 years), while 7.7% (3/39 patients) were categorized as young adult or 25-44 years old and 15.4% (6/39 patients) were included in elderly category or above 65 years old (Table 1). Pus culture showed microbial growth in 29 patients (74.4%) while 10 patients (25.6%) showed no microbial growth.

Deleted[AN]: 1

Table 1. Demographic information of DM patient with gangrene

Sample	Number of patients (Percentage)
Gender	
Male	19 (48.7)
Female	20 (51.3)
Age (years)	
25-44	3 (7.7)
45-59	30 (76.9)



60-75	6 (15.4)
-------	----------

Pus culture showed the appearance of microbial drug resistance organisms (MDRO) which is *Escherichia coli*- extended spectrum beta lactamase (ESBL) in 4 patients (13.8%). Our result also found another MDRO which is methicillin resistant *Staphylococcus aureus* (MRSA) in 3 patients (10.4%) (Table 2). In comparison the appearance of gram-negative bacteria is dominant compare to gram-positive bacteria (72.4% compare to 27.6%). In case of gram negative, the study showed Enterobacteriaceae were seen enormously causing gangrene in DM patients such as *Klebsiella pneumoniae* (3 patients, 10.4%), *Proteus mirabilis* (3 patients, 10.4%).

Table 2. Bacterial profile causing gangrene among DM patient from pus sample

No	Bacteria	Number (Percentage)
Gram negative bacteria		
1	<i>Escherichia coli (ESBL)</i>	4 (13.8)
2	<i>Klebsiella pneumoniae</i>	3 (10.4)
3	<i>Proteus mirabilis</i>	3 (10.4)
4	<i>Citrobacter freundii</i>	2 (6.9)
5	<i>Citrobacter koseri</i>	2 (6.9)
6	<i>Enterobacter cloacae</i>	2 (6.9)
7	<i>Enterobacter aerogenes</i>	1 (3.5)
8	<i>Morganella morganii</i>	1 (3.5)
9	<i>Proteus hauseri</i>	1 (3.5)
10	<i>Shigella sp</i>	1 (3.5)
11	<i>Pseudomonas putida</i>	1 (3.5)
Gram positive bacteria		
12	Methicillin Resistant <i>Staphylococcus aureus</i> (MRSA)	3 (10.4)
13	<i>Enterococcus faecalis</i>	2 (6.9)
14	<i>Enterococcus avium</i>	1 (3.5)
15	<i>Staphylococcus haemolyticus</i>	1 (3.5)
16	<i>Staphylococcus hominis</i>	1 (3.5)
Total		29 (100)



Antibiotic resistance test showed that gram negative bacteria showed resistant to ampicillin (penicillin type of antibiotic), cefazolin (cephalosporin type of antibiotic) (Table 3). Through antibiotic resistance test, we found *Pseudomonas putida* showed resistance to almost all antibiotic tested except ampicillin and ampicillin sulbactam, meropenem and furantoin (Table 3). In case of *E. coli* ESBL it is shown that beside cephalosporin resistance (cefazolin, ceftriaxone), it was also showed resistance to ampicillin and ciprofloxacin (Table 3). While *E. coli*- ESBL showed susceptibility to carbapenem antibiotics such as ertapenem and meropenem; aminoglikosida such as amikacin; furantoin, amikacin and tigecycline. Other gram-negative bacteria showed resistance to cephalosporins (cefazolin) and penicillin class (ampicillin) (Table 3). But it showed susceptibility to carbapenem class (ertapenem and meropenem); aminoglikosida class (amikacin and gentamicin); beta lactamase inhibitor class alone or in combination with penicillin class (azretonam, piperacillin tazobactam); class cephalosporins (ceftazidime, ceftriaxone, cefepime) (Table 4).

Table 3. Antibiotic Resistance Results from Gram Negative Bacteria Causing Gangrene among DM patients

Antibiotics	AMP	SAM	TZP	KZ	CAZ	CRO	FEP	ATM	ERT A	ME M	AK	GN	CIP	F	SXT	TGC
<i>Escherichia coli</i> (ESBL) n=4 (%)	4 (100)	2 (50)	1 (25)	4 (100)	2 (50)	4 (100)	1 (25)	3 (75)	0 (0)	0 (0)	0 (0)	1 (25)	4 (100)	0 (0)	3 (75)	0 (0)
<i>Klebsiella pneumoniae</i> n=3 (%)	0 (0)	1 (33)	0 (0)	2(67)	2 (67)	2 (67)	2 (67)	2 (67)	0 (0)	0 (0)	0 (0)	2 (67)	3 (100)	0 (0)	1 (33)	0 (0)
<i>Proteus mirabilis</i> n=3 (%)	2 (67)	1 (33)	1 (33)	3 (100)	1 (33)	1 (33)	1 (33)	2 (67)	0 (0)	0 (0)	0 (0)	1 (33)	1 (33)	3 (100)	2 (67)	2 (67)
<i>Citrobacter freundii</i> n=2 (%)	2 (100)	2 (100)	0 (0)	2 (100)	0 (0)	1 (50)	0 (0)	1 (50)	0 (0)	0 (0)	0 (0)	1 (50)	1 (50)	0 (0)	1 (50)	0 (0)
<i>Citrobacter koseri</i> n=2 (%)	2 (100)	0 (0)	0 (0)	1 (50)	0 (0)	0 (0)	0 (0)	0 (0)	0(0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Enterobacter cloaee</i> n=2 (%)	2 (100)	2 (100)	1 (50)	2 (100)	1 (50)	1 (50)	0 (0)	1 (50)	0 (0)	0 (0)	0 (0)	0 (0)	2 (100)	0 (0)	1 (50)	0 (0)
<i>Enterobacter aerogenes</i> n=1(%)	1 (100)	1 (100)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Proteus hauseri</i> n=1(%)	1 (100)	1 (100)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Morganella morganii</i> n=1(%)	1 (100)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Shigella sp</i> n=1(%)	1 (100)	1 (100)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)	1 (100)	1 (100)	0 (0)
<i>Pseudomonas</i>	0	0	1	1	1	1	1	1	1	0	1	1	1	0	1	1



<i>putida</i> n=1(%)	(0)	(0)	(100)	(100)	(100)	(100)	(100)	(100)	(100)	(0)	(100)	(100)	(100)	(0)	(100)	(100)
----------------------	-----	-----	-------	-------	-------	-------	-------	-------	-------	-----	-------	-------	-------	-----	-------	-------

AMP, Ampicillin; SAM, Ampicillin Sulbactam; TZP, Piperacillin Tazobactam; KZ, Cefazolin; CAZ, Ceftazidime; CRO, Ceftriaxone; FEP, Cefepim; ATM, Azteronam; ERTA, Ertapenem; MEM, Meropenem; AK, Amikacin; GN, Gentamicin; CIP, Ciprofloxacin; F, Nitrofurantoin; SXT, Trimethoprim/sulfamethoxazole; TGC, Tigecycline.

Table 4. Antibiotic Susceptibility Results from Gram Negative Bacteria Causing Gangrene among DM patient

Antibiotics	AMP	SAM	TZP	KZ	CAZ	CRO	FEP	ATM	ERT A	MEM	AK	GN	CIP	F	SXT	TGC
<i>Escherichia coli</i> (ESBL) n=4 (%)	0 (0)	0 (0)	3 (75)	0 (0)	2 (50)	0 (0)	3 (75)	1 (25)	4 (100)	4 (100)	4 (100)	3 (75)	0 (0)	4 (100)	1 (25)	4 (100)
<i>Klebsiella pneumoniae</i> n=3 (%)	3 (100)	1 (33)	3 (100)	0 (0)	1 (33)	1 (33)	1 (33)	1 (33)	3 (100)	3 (100)	3 (100)	1 (33)	0 (0)	0 (0)	2 (67)	0 (0)
<i>Proteus mirabilis</i> n=3 (%)	1 (33)	2 (67)	2 (67)	0 (0)	2 (67)	2 (67)	2 (67)	1 (33)	1 (33)	3 (100)	3 (100)	2 (67)	2 (67)	0 (0)	1 (33)	0 (0)
<i>Citrobacter freundii</i> n=2 (%)	0 (0)	0 (0)	1 (50)	0 (0)	1 (50)	1 (50)	2 (100)	0 (0)	2 (100)	2 (100)	2 (100)	1 (50)	1 (50)	1 (50)	1 (50)	2 (100)
<i>Citrobacter koseri</i> n=2 (%)	0 (0)	1 (50)	2 (100)	0 (0)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	0 (0)	2 (100)	1 (50)
<i>Enterobacter cloaee</i> n=2 (%)	0 (0)	0 (0)	1 (50)	0 (0)	1 (50)	1 (50)	2 (100)	1 (50)	1 (50)	2 (100)	2 (100)	2 (100)	0 (0)	0 (0)	1 (50)	1 (50)
<i>Enterobacter aerogenes</i> n=1(%)	0 (0)	0 (0)	1 (100)	0 (0)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	0 (0)	1 (100)	1 (100)
<i>Proteus hauseri</i> n=1(%)	0 (0)	0 (0)	1 (100)	0 (0)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	0 (0)	1 (100)	0 (0)
<i>Morganella morganii</i> n=1(%)	0 (0)	0 (0)	1 (100)	0 (0)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	0 (0)	1 (100)	0 (0)
<i>Shigella sp</i> n=1(%)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)	1 (100)	1 (100)	1 (100)	0 (0)	1 (100)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Pseudomonas putida</i> n=1(%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

AMP, Ampicillin; SAM, Ampicillin Sulbactam; TZP, Piperacillin Tazobactam; KZ, Cefazolin; CAZ, Ceftazidime; CRO, Ceftriaxone; FEP, Cefepim; ATM, Azteronam; ERTA, Ertapenem; MEM, Meropenem; AK, Amikacin; GN, Gentamicin; CIP, Ciprofloxacin; F, Nitrofurantoin; SXT, Trimethoprim/sulfamethoxazole; TGC, Tigecycline.

The results of antibiotic resistance test of gram-positive bacteria showed resistant to tetracyclin and ciprofloxacin. Apart from beta lactam antibiotics, MRSA showed resistance to aminoglycosides class (gentamicin), tetracycline, fluoroquinolone class (moxifloxacin, levofloxacin, ciprofloxacin), lincomycin class (clindamycin) and macrolides class (clindamycin) (Table 5). MRSA showed susceptibility to tigecycline, linezolid, vancomycin and furantoin. Others gram positive bacteria showed susceptible to linezolid, vancomycin, tigecycline, ampicillin (Table 6). While other gram-positive bacteria showed resistance to tetracycline and showed susceptibility to linezolid and vancomycin (Table 5 and 6).



Table 5. Antibiotic Resistance Results from Gram Positive Bacteria Causing Gangrene among DM patients

Antibiotics	AMP	OXA	BEN	GN	TGC	SXT	TE	MXF	LEV	CIP	CC	LZD	VA	E	F	Rif
<i>Methicillin Resistant Staphylococcus aureus</i> (MRSA) n=3 (%)	0 (0)	3 (100)	0 (0)	3 (100)	0 (0)	1 (33)	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)	0 (0)	0 (0)	3 (100)	0 (0)	2 (67)
<i>Enterococcus faecalis</i> n=2 (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (50)	0 (0)	0 (0)
<i>Enterococcus avium</i> n=1 (%)	0 (0)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)	0 (0)
<i>Staphylococcus haemolyticus</i> n=1 (%)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)	0 (0)	1 (100)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Staphylococcus hominis</i> n=1 (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

AMP, Ampicillin; OXA, Oxacillin; BEN, Benzylpenicillin; GN, Gentamicin; TGC, Tigecycline; SXT, Trimethoprim Sulfamethoxazole; TE, Tetracycline; MXF, Moxifloxacin; LEV, Levofloxacin; CIP, Ciprofloxacin; CC, Clindamycin; LZD, Linezolid; VA, Vancomycin; E, Erythromycin; F, Nitrofurantoin; Rif, Rifampicin.

Antibiotics	AMP	OXA	BEN	GN	TGC	SXT	TE	MXF	LEV	CIP	CC	LZD	VA	E	F	Rif
<i>Methicillin Resistant Staphylococcus aureus</i> (MRSA) n=3 (%)	0 (0)	0 (0)	0 (0)	0 (0)	3 (100)	1 (33)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (100)	3 (100)	0 (0)	3 (100)	1 (33)
<i>Enterococcus faecalis</i> n=2 (%)	2 (100)	0 (0)	0 (0)	0 (0)	2 (100)	0 (0)	0 (0)	0 (0)	2 (100)	2 (100)	0 (0)	2 (100)	2 (100)	0 (0)	1 (50)	0 (0)
<i>Enterococcus avium</i> n=1 (%)	1 (100)	0 (0)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)	1 (100)	0 (0)	0 (0)	0 (0)
<i>Staphylococcus haemolyticus</i> n=1 (%)	0 (0)	0 (0)	1 (100)	1 (100)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)	1 (100)	1 (100)	1 (100)	0 (0)	1 (100)
<i>Staphylococcus hominis</i> n=1 (%)	0 (0)	0 (0)	0 (0)	1 (100)	0 (0)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	0 (0)	1 (100)	0 (0)	1 (100)	1 (100)	0 (0)

Table 6. Antibiotic Susceptibility Results from Gram Positive Bacteria Causing Gangrene among DM patients
Sulfamethoxazole; TE, Tetracycline; MXF, Moxifloxacin; LEV, Levofloxacin; CIP, Ciprofloxacin; CC, Clindamycin; LZD, Linezolid; VA, Vancomycin; E, Erythromycin; F, Nitrofurantoin; Rif, Rifampicin.

DISCUSSION

Demographic information of DM patient reveals that in term of gender there is no different in probability of DM patient to develop gangrene. While in term of age, DM patients in group of 45-59 years old showing high probability of developing gangrene. This study also in accordance with other



studies by Tong et al in 2020 that stated DFU (diabetic foot ulcers) is common in middle-aged patients. Also study conducted in Saudi Arabia that showed > 45 years of age can poses a threat for developing DFU (Al-Rubeaan *et al.*, 2015; AlSadrah, 2019). Our study demonstrated that middle-aged patients with DFUs had worse glycemic control, made worse lifestyle decisions like smoking and drinking, had more severe ulcers, and were more likely to have microangiopathy problems. However, these individuals subsequently recovered more quickly and were at a lower risk of death and significant amputation (Tong *et al.*, 2020).

Our result showed that bacterial found in pus culture dominated by gram negative bacteria. With *E. coli* ESBL, MRSA, *Klebsiella pneumoniae*, *Proteus mirabilis* being the most common bacteria causing gangrene. Gram-negative rods were mostly found in patients with chronic wounds that had already been treated. Beginning in the late 1970s, studies showed that aerobic Gram-positive cocci, particularly *Staphylococcus aureus*, were the most common pathogens in DFIs, frequently as monomicrobial infections. Aerobic DFIs brought on by multidrug-resistant organisms, including extended-spectrum beta-lactamase-producing Gram-negative rods (Varaiya *et al.*, 2008) or methicillin-resistant *S. aureus* (MRSA), have become a significant issue in recent years. The choice of an agent active against that isolate is undoubtedly necessary in the event of an infection with an antibiotic-resistant bacterium, but therapeutic management should remain unchanged (Uçkay *et al.*, 2012).

When we adding the number of *E. coli* ESBL and MRSA we found that 24 % cases were causing by Multidrug-resistant bacterial infection. Another factor contributing to the appearance of MDRO in other study by Dubsky et al in 2013 were because of long term poor glucose control in DM patient (Dubský *et al.*, 2013). By reducing the therapeutic efficacy of antibiotic therapy, MDRO infection in diabetic foot ulcers makes treatment more difficult and may even result in fatalities or amputations (Agbi et al., 2017; Yan et al., 2022). The risk factors of drug-resistant negative bacilli in patients should be assessed in the development of the initial anti-infective treatment regimen in clinical practice due to the increased resistance rate of *E. coli* ESBL among gram-negative bacteria. Another study also noted that the appearance of MDRO might be related to the patients with serious illness admitted to our hospital as a tertiary care hospital and the more complex history of antibacterial drug use (Yan *et al.*, 2022).

Systemic antibiotic therapy is required for patients with poor systemic resistance, which typically coexists with bacteremia or sepsis. As a result, it's crucial to perform a thorough evaluation of each patient with diabetic foot ulcers, keep an eye on the severity of the infection and any changes in the pathogenic bacteria, and administer anti-infective therapy in a consistent manner (Tang, 2019).The

Deleted[AN]: i

Formatted[AN]: Font: Italic



majority of diabetic foot infections (DFIs) require systemic antibiotic therapy, with empirical selection being the norm at first. Even though there are numerous antibiotics available, it is unclear which one is best for treating DFIs. Antibiotic susceptibility that gram negative bacteria (wild type and MDRO) showed susceptibility to meropenem class, aminoglikosida class and beta lactamase inhibitor antibiotic. While for gram negative bacteria without MDRO, cephalosporin, beta lactamase antibiotics still susceptible in this study. In case of gram-positive bacteria, it showed susceptibility to tigecycline, linezolid, vancomycin. Other studies suggested that ertapenem with or without vancomycin also tigecycline can be used to treat DFI infection (Selva Olid *et al.*, 2015). Study by Du et al in 2022 also showed that gram positive bacteria were susceptible to linezolid, vancomycin, teicoplanin (Du *et al.*, 2022).

CONSLUSION

The gangrene or diabetic foot infection occur in the middle age group (45-59 years) old accounted for 76.9%. Pus culture showed *E. coli* ESBL, MRSA, *Klebsiella pneumoniae*, *Proteus mirabilis* as the dominant bacteria found. Gram negative bacteria were highly sensitive to meropenem class (ertapenem and meropenem, aminoglikosida class (amikacin, gentamicin) and tigecycline class of antibiotics *Ertapenem*, meropenem, amikacin, gentamicin, piperacillin tazobactam. While gram positive bacteria were highly sensitive to tigecycline, linezolid and vancomycin.

ACKNOWLEDGMENTS

The authors wanted to thank East Java Province Government Hospital for giving us the provided research materials. We also wanted to thanked all member of Microbiology department in that hospital for their guidance in helping collecting secondary data. The authors state there is no conflict of interest with the parties involved in this study.

REFERENCES

1. Agbi, K.E., Carvalho, M., Phan, H. and Tuma, C. 2017. Case Report: Diabetic Foot Ulcer Infection Treated with Topical Compounded Medications. *International Journal of Pharmaceutical Compounding*. Vol. 21 (1). Pp. 22–27.
2. Al-Rubeaan, K., Al Derwish, M., Ouizi, S., Youssef, A.M., Subhani, S.N., Ibrahim, H.M. and Alamri, B.N. 2015. Diabetic foot complications and their risk factors from a large retrospective cohort study.



- PloS One. Vol. 10 (5). Pp. e0124446.
3. AlSadrah, S.A. 2019. Impaired quality of life and diabetic foot disease in Saudi patients with type 2 diabetes: A cross-sectional analysis. SAGE Open Medicine Ltd. Vol. 7. Pp. 2050312119832092.
 4. Apelqvist, J., Elgzyri, T., Larsson, J., Löndahl, M., Nyberg, P. and Thörne, J. 2011. Factors related to outcome of neuroischemic/ischemic foot ulcer in diabetic patients. Journal of Vascular Surgery. Vol. 53 (6) Pp. 1582–8.e2.
 5. Belefquih, B., Frikh, M., Benlahlou, Y., Maleh, A., Jadid, L., Bssaibis, F., Ghazouani, M., et al. 2016. Diabetic Foot Infection in Morocco: Microbiological Profile. Wounds : A Compendium of Clinical Research and Practice. Vol. 28 (3). Pp. 89–98.
 6. Bowler, P.G., Duerden, B.I. and Armstrong, D.G. 2001. Wound microbiology and associated approaches to wound management. Clinical Microbiology Reviews. Vol. 14 (2). Pp. 244–269.
 7. Chen, Y., Ding, H., Wu, H. and Chen, H.-L. 2017. The Relationship Between Osteomyelitis Complication and Drug-Resistant Infection Risk in Diabetic Foot Ulcer: A Meta-analysis. The International Journal of Lower Extremity Wounds. Vol. 16 (3). Pp. 183–190.
 8. Du, F., Ma, J., Gong, H., Bista, R., Zha, P., Ren, Y., Gao, Y., et al. 2022. Microbial Infection and Antibiotic Susceptibility of Diabetic Foot Ulcer in China: Literature Review. Frontiers in Endocrinology. Vol. 13(May). Pp. 1–9.
 9. Dubský, M., Jirkovská, A., Bem, R., Fejfarová, V., Skibová, J., Schaper, N.C. and Lipsky, B.A. 2013. Risk factors for recurrence of diabetic foot ulcers: prospective follow-up analysis in the Eurodiale subgroup. International Wound Journal. Vol. 10 (5). Pp. 555–561.
 10. Fejfarová, V., Jirkovská, A., Skibová, J. and Petkov, V. 2002. Pathogen resistance and other risk factors in the frequency of lower limb amputations in patients with the diabetic foot syndrome. Vnitřní lékařství. Vol. 48 (4). Pp. 302–306.
 11. Gershater, M.A., Löndahl, M., Nyberg, P., Larsson, J., Thörne, J., Eneroth, M. and Apelqvist, J. 2009. Complexity of factors related to outcome of neuropathic and neuroischaemic/ischaemic diabetic foot ulcers: a cohort study. Diabetologia. Vol. 52 (3). Pp. 398–407.
 12. International Diabetes Federation (IDF). 2019. “IDF Diabetes Atlas”, 9th Edn. Available from: https://diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf. Access from December 12, 2022.
 13. Johannesson, A., Larsson, G.-U., Ramstrand, N., Turkiewicz, A., Wiréhn, A.-B. and Atroshi, I. 2009. Incidence of lower-limb amputation in the diabetic and nondiabetic general population: a 10-year



population-based cohort study of initial unilateral and contralateral amputations and reamputations. *Diabetes Care*. Vol. 32 (2). Pp. 275–280.

14. Johnson, S., Lebahn, F., Peterson, L.R. and Gerding, D.N. 1995. Use of an anaerobic collection and transport swab device to recover anaerobic bacteria from infected foot ulcers in diabetics. *Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America*. Vol. 20 (Suppl 2). Pp. S289-90.
15. Mantey, I., Hill, R.L., Foster, A. V, Wilson, S., Wade, J.J. and Edmonds, M.E. 2000. Infection of foot ulcers with *Staphylococcus aureus* associated with increased mortality in diabetic patients. *Communicable Disease and Public Health*. Vol. 3 (4). Pp. 288–290.
16. Saltoglu, N., Ergonul, O., Tulek, N., Yemisen, M., Kadanali, A., Karagoz, G., Batirel, A., et al. 2018. Influence of multidrug resistant organisms on the outcome of diabetic foot infection. *International Journal of Infectious Diseases*. Vol. 70, Pp. 10–14.
17. Schaper, N.C., Van Netten, J.J., Apelqvist, J., Lipsky, B.A. and Bakker, K. 2017. Prevention and management of foot problems in diabetes: A Summary Guidance for Daily Practice 2015, based on the IWGDF guidance documents. *Diabetes Research and Clinical Practice*. Vol. 124. Pp. 84–92.
18. Selva Olid, A., Solà, I., Barajas-Nava, L.A., Gianneo, O.D., Bonfill Cosp, X. and Lipsky, B.A. 201. Systemic antibiotics for treating diabetic foot infections. *The Cochrane Database of Systematic Reviews*. Vol. 2015 (9). Pp. CD009061.
19. Spreen, M.I., Gremmels, H., Teraa, M., Sprengers, R.W., Verhaar, M.C., Statius van Eps, R.G., de Vries, J.-P.P.M., et al. 2016. Diabetes Is Associated With Decreased Limb Survival in Patients With Critical Limb Ischemia: Pooled Data From Two Randomized Controlled Trials. *Diabetes Care*. Vol. 39 (11). Pp. 2058–2064.
20. Tang, Z.Y. 2019. The comprehension to the part of diabetic foot infection in Chinese guideline on prevention and management of diabetic foot (2019 edition). *World Clini Drugs*. Vol. 40 (9). Pp. 599–602.
21. Tong, T., Yang, C., Tian, W., Liu, Z., Liu, B., Cheng, J., Cheng, Q., et al. 2020. Phenotypes and outcomes in middle-aged patients with diabetic foot ulcers: A retrospective cohort study. *Journal of Foot and Ankle Research*. Vol. 13 (1). Pp. 1–8.
22. Uçkay, I., Lübbecke, A., Harbarth, S., Emonet, S., Tovmirzaeva, L., Agostinho, A., Longtin, Y., et al. 2012. Low risk despite high endemicity of methicillin-resistant *Staphylococcus aureus* infections



- following elective total joint arthroplasty: A 12-year experience. *Annals of Medicine*. Vol. 44 (4). Pp. 360–368.
23. Varaiya, A., Dogra, J., Kulkarni, M. and Bhalekar, P. 2008. Extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in diabetic foot infections. *Indian Journal of Pathology and Microbiology*. Vol. 51 (3). Pp. 370–372.
24. Williams, D.T., Hilton, J.R. and Harding, K.G. 2004. Diagnosing foot infection in diabetes. *Clinical Infectious Diseases*. Vol. 39 (Suppl 2). Pp. S83-6.
25. Yan, X., Song, J.-F., Zhang, L. and Li, X. 2022. Analysis of risk factors for multidrug-resistant organisms in diabetic foot infection. *BMC Endocrine Disorders*. Vol. 22 (1). Pp. 46.


BUKTI KORESPONDENSI
ARTIKEL JURNAL NASIONAL SINTA 2

Judul artikel: Bacterial Profile and Antibiotic Susceptibility Test among Diabetes Mellitus Patients with Gangrene in Surabaya

Jurnal : Journal of Vocational Health Studies, 7 (No. 3)

Author : Imro'atul Qona'ah, 'Aliyah Siti Sundari, Ratna Wahyuni, Dwi Wahyu Indriati

No	Perihal	Tanggal
3	Bukti pengiriman revisi I	1 April 2023






BUKTI KORESPONDENSI
ARTIKEL JURNAL NASIONAL SINTA 2

Judul artikel: Bacterial Profile and Antibiotic Susceptibility Test among Diabetes Mellitus Patients with Gangrene in Surabaya

Jurnal : Journal of Vocational Health Studies, 7 (No. 3)

Author : Imro'atul Qona'ah, 'Aliyah Siti Sundari, Ratna Wahyuni, Dwi Wahyu Indriati

No	Perihal	Tanggal
4	Bukti penerimaan revisi II	21 Agustus 2023

 Journal of Vocational Health Studies  

[← Back to Submissions](#)

Revisions [Q Search](#) [Upload File](#)

No Files

Review Discussions [Add discussion](#)

Name	From	Last Reply	Replies	Closed
JVHS-Hasil Tinjau Naskah A dan B	dinyamalia 2023-03-08 12:02 PM	dwiwahyu 2023-04-01 09:28 AM	1	<input type="checkbox"/>
JVHS-Reminder	dinyamalia 2023-03-27 12:28 PM	-	0	<input type="checkbox"/>
JVHS-Result of Revision by Chief	dinyamalia 2023-08-21 02:04 PM	-	0	<input type="checkbox"/>

[https://e-journal.unair.ac.id/JVHS/\\$\\$\\$call\\$\\$/tab/author-dashboard/author-dashboard-review-round-tab/fetch-review-round-info?submissionId=41535&stageId=3&reviewRoundId=22753](https://e-journal.unair.ac.id/JVHS/$$$call$$/tab/author-dashboard/author-dashboard-review-round-tab/fetch-review-round-info?submissionId=41535&stageId=3&reviewRoundId=22753)



Bacterial Profile and Antibiotic Susceptibility Test among Diabetes Mellitus Patients with Gangrene in Surabaya

Profil Bakteri dan Uji Kerentanan Antibiotik pada Pasien Diabetes Melitus dengan Gangren di Surabaya

Imro`atul Qona`ah¹, Aliyah Siti Sundari¹, Ratna Wahyuni¹, Dwi Wahyu Indriati^{1*}

¹ Department of Health, Faculty of Vocational Studies, Universitas Airlangga, Indonesia, imroaiim01@gmail.com; aliyahsitisundari@gmail.com; ratna.wahyuni@vokasi.unair.ac.id; dwiwahyu.indriati@vokasi.unair.ac.id* (*for corresponding author)

ABSTRACT

Background: Gangrene is a severe complication of damaged tissue that can occur in people with diabetes mellitus and putting them at risk for bacterial infection. Pus culture can show diabetic gangrene patients' infecting bacteria. **Purpose:** This study aims to determine the prevalence of infection-causing bacteria and antibiotic sensitivity tests in diabetic gangrene patients at Haji Regional General Hospital, East Java Province, for January-December 2021. **Methods:** The method used in this study is Observational Analytical Cross-Sectional, which is based on secondary data and is analyzed using the percentage formula and chi-square test. **Results:** The data obtained from 39 patients revealed 29 (74.4%) positive patients for bacterial infection. The Gram-negative bacteria were found to be the cause of infection more frequently (72.41%) than the Gram-positive bacteria (27.59%). The prevalence of Gram-negative bacteria species most frequently from *Escherichia coli* (ESBL) 13.79% (4/29), *Klebsiella pneumoniae* 10.35% (3/29), *Proteus mirabilis* 10.35% (3/29). While the dominant Gram-positive bacteria a Methicillin-Resistant *Staphylococcus aureus* (MRSA) 10.35% (3/29). The antibiotic sensitivity test showed that Gram-negative group were susceptible to Ertapenem, Meropenem, Amikacin, Gentamicin, Piperacillin Tazobactam while resistant to Ampicillin and Cefazolin. The antibiotic sensitivity tests showed that the Gram-positive group were susceptible to Linezolid, Vancomycin and Tigecycline while resistant to Tetracycline and Ciprofloxacin. **Conclusion:** it is importance to screen the bacterial profile causing gangrene and their antibiotic susceptibility pattern in DM patients in order to give a proper treatment for DM patients



Keywords: antibiotic resistance, diabetes melitus, *E. coli*, gangrene, pus

ABSTRAK

Latar Belakang: Gangren merupakan komplikasi serius berupa jaringan rusak yang dapat terjadi pada penderita diabetes melitus dan sangat berisiko mengalami infeksi bakteri. Pemeriksaan menggunakan kultur pus dapat menunjukkan bakteri penyebab infeksi pada penderita gangren diabetik. **Tujuan:** Penelitian ini bertujuan untuk mengetahui prevalensi bakteri penyebab infeksi dan uji kepekaan antibiotik pada penderita gangren diabetik di Rumah Sakit Umum Daerah Haji Provinsi Jawa Timur periode Januari - Desember 2021. **Metode:** Metode yang digunakan pada penelitian adalah *Observational Analytical Cross Sectional* dari data sekunder, yang dianalisis dengan rumus presentase dan *chi square*. **Hasil:** Hasil data yang diperoleh dari total 39 pasien yaitu 29 (74,4%) pasien positif terinfeksi bakteri. Bakteri penyebab infeksi tertinggi oleh kelompok Gram-negatif yaitu 72,41% (21/29), dan bakteri Gram-positif yaitu 27,59 % (8/29). Prevalensi spesies bakteri Gram-negatif yang dominan oleh *Escherichia coli* (ESBL) 13,79% (4/29), *Klebsiella pneumoniae* 10,35% (3/29), dan *Proteus mirabilis* 10,35% (3/29). Sedangkan pada Gram positif dominan oleh *Methicilin-Resistant Staphylococcus aureus* (MRSA) 10,35% (3/29). Uji kepekaan antibiotik yang diperoleh berdasarkan kelompok Gram-negatif yang sensitif adalah *Ertapenem*, *Meropenem*, *Amikacin*, *Gentamicin*, *Piperacillin Tazobactam* serta resistan terhadap *Ampicillin* dan *Cefazoline*. Uji kepekaan antibiotik untuk kelompok Gram-positif sensitif terhadap *Linezolid*, *Vancomycin* dan *Tigecycline*. Sedangkan antibiotik yang resistan yaitu *Tetracycline* dan *Ciprofloxacin*. **Kesimpulan:** hasil dari penelitian ini menunjukkan perlunya skrining untuk melihat profil bakteri penyebab gangrene beserta pola kerentanannya terhadap antibiotik pada pasien DM sehingga dapat memberikan pengobatan yang tepat pada pasien DM.

Kata kunci: DM, *E. coli*, gangrene, pus, resistensi antibiotik

INTRODUCTION

Diabetes mellitus is a rapidly spreading health problem. In 2045, 700 million adults worldwide are predicted to have the disease (International Diabetes Federation (IDF), 2019). Diabetes patient commonly experience foot complications. Diabetes patients frequently experience foot problems, with foot ulcers being one of the more devastating effects. If diabetic foot infections (DFI) are not promptly and properly treated, these ulcers frequently get infected and can result in septic gangrene and amputation. Amputation is a possibility with diabetic foot ulcers (DFUs), a serious consequence of diabetes mellitus (Apelqvist *et*



al., 2011; Spreen *et al.*, 2016). Studies have indicated that diabetes persons are eight times more likely to experience a vascular lower limb amputation at or near the trans-metatarsal level than nondiabetic individuals under the age of 45 (Johannesson *et al.*, 2009).

The most common way to define diabetic foot infections is as an inflammatory reaction and tissue harm brought on by an interaction between the host and microbial pathogens (Williams *et al.*, 2004). Reduced peripheral circulation, inflammation, and infection have all been put out as potential causes of gangrene, though these theories have been contested (Gershater *et al.*, 2009; Schaper *et al.*, 2016). Although a few studies have described certain filamentous fungi and yeasts as the etiological agents of diabetic foot infections, the majority of infections in the diabetic foot are of aerobic and anaerobic bacterial origin, and in most cases polymicrobial (Akhi *et al.*, 2015; Manharpreet Kaur *et al.*, 2022).

Gram-positive bacteria like *Staphylococcus aureus* and *Enterococcus faecalis*, together with Gram-negative bacteria like *Escherichia coli* and *Pseudomonas aeruginosa*, were shown to be the most prevalent flora of diabetic foot infections, according to earlier investigations (Alhubail *et al.*, 2020; Heravi *et al.*, 2019). With the advancement of diabetes epidemiology and modifications in the use of antimicrobial medications, the bacterial spectrum of diabetic foot infections has changed significantly in recent years (Chen *et al.*, 2017; Saltoglu *et al.*, 2018). It is crucial to concentrate on evaluating the risk factors of multi-drug resistant bacterial infections in order to find a more effective treatment because the increasingly severe form of prevention and treatment of diabetic foot ulcer infections is associated with a high rate of detection of multi-drug resistant bacteria (Agbi *et al.*, 2017; Belefquih *et al.*, 2016). Commonly in diabetic foot infection we can find Methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant *Enterococcus* (VRE), Enterobacteriaceae that produce ultra-broad spectrum - lactamases (ESBLs), such as *Escherichia coli* and *Klebsiella pneumoniae*, carbapenem-resistant Enterobacteriaceae, multidrug-resistant *Pseudomonas aeruginosa* (MDR-PA) (Yan *et al.*, 2022). Thus, this study aims to listed bacterial profile causing gangrene (wet gangrene) among diabetic patient in Surabaya.

MATERIAL AND METHOD

Study site and population

A descriptive observational analysis study was carried out from January to December 2021 at East Java Province Government Hospital, Surabaya Indonesia. The ethical clearance was obtained from ethical committee of this hospital. This hospital is a government building which also act as a teaching facility.



With at least 200 beds, this hospital is classified as a type B hospital in Indonesia, and patients with National Health Insurance coverage are welcome to receive care there. Additionally, several district hospitals in Surabaya and the province of East Java used this hospital as their model facility. This hospital offers seventeen different specialties, including pediatrics, anesthesia, dental specialties, internal medicine, radiology, and others.

Data and specimen collection

Wound bed swab sample was collected from 39 DM patients with gangrene. Levine's Technique was used to collect surface swabs, which involves rotating a wound swab over a 1 cm² area of the wound for 5 seconds while applying enough pressure to draw fluid from the inner portion of the wound bed. The swab then transported with Amies nutritional growth medium (Labware, USA). Within 20 minutes, the specimens had been packaged in sterile transport containers and delivered to the microbiology facility for aerobic culturing. Samples were then processed to the Microbiology Laboratory Department.

Culture and identification techniques

Swab samples were inoculated onto plates of 5% blood agar, MacConkey agar (Oxoid Ltd, Basingstoke, UK). Incubation was carried out overnight under aerobic conditions at 37°C. The next day visible colony and pure colony were then collected and transferred to inoculum tube containing 3ml NaCl 0.45% pH 5.0. In order to preserve pure cultures, subcultures of many distinct colonies were carried out in cultures that were yielding more than one bacterium. The density of the suspension then checked with densitometer (Grant Instruments, UK). The measured density should show 0,5-0,63 McFarland. The inoculum tube then placed in front of the ID card and another tube in front of the AST card. Then loaded into VITEK2 system. The VITEK® 2 device (bioMérieux, USA) was utilized to identify the isolates using conventional bacteriological techniques and biochemical testing.

Antimicrobial Susceptibility Testing

Antibiotics sensitivity testing was performed on sensitivity test agar using VITEK® 2 apparatus (bioMérieux, USA) in accordance with National Committee for Clinical Laboratory Standards. Antibiotic class penicillin (ampicillin); penicillin and beta lactamase inhibitor (ampicillin sulbactam, piperacillin tazobactam), class cephalosporins (cefazolin, ceftazidime, ceftriaxone, cefepime), class carbapenems (ertapenem, meropenem), class beta lactamase inhibitor (aztreonam), class nitrofurantoin (nitrofurantoin),



class aminoglycosides (amikacin, gentamicin), class fluoroquinolones (ciprofloxacin), and class glycycline (tigecycline) were used for Gram-negative bacteria. Antibiotic class penicillin (ampicillin, oxacillin, benzylpenicillin); class aminoglycosides (gentamicin); class glycycline (tigecycline); class sulfonamides (trimethoprim/sulfamethoxazole); class tetracycline (tetracyclin); class fluoroquinolones (moxifloxacin, levofloxacin, ciprofloxacin); class lincomycin (clindamycin); class oxazolidinone (linezolid), class glycopeptide (vancomycin), class macrolides (erythromycin); class nitrofurantoin (nitrofurantoin) and class rifampisin (rifampisin) were used for Gram-positive bacteria. Antibiotics were classified using the 2019 WHO AwaRe (Access, Watch, Reserve) classification of antibiotics for evaluation and monitoring of use. Results were classified as either resistant (R) or sensitive (S) to the tested antibiotics using the interpretive guidelines given by the Clinical and Laboratory Standards Institute (CLSI). The tested antibiotics can still be utilized for therapy because of the sensitive results. Since there are bacterial resistances to the antibiotics being tested in this investigation, the readings utilizing this technique (S or R type) reveal this. Multi-Drug Resistance was defined as bacterial isolates that were resistant to three or more antimicrobials from various structural classes (MDR).

Statistical analysis

The results obtained in this study are number of bacteria based on species identification and results of antibiotic susceptibility tests. Categorical data is presented in the form of frequency and percentage.

RESULT

Our results show that among 39 DM patient with gangrene, 19 patients (48.3%) were male and 20 patients (51.7%) were female. Among those patients, 76.9% (30/39 patients) were included in productive age category (45-59 years), while 7.7% (3/39 patients) were categorized as young adult or 25-44 years old and 15.4% (6/39 patients) were included in elderly category or above 65 years old (Table 1). Pus culture showed microbial growth in 29 patients (74.4%) while 10 patients (25.6%) showed no microbial growth.

Table 1. Demographic information of DM patient with gangrene



Patient Number	Gender	Age	Bacterial Growth
1.	Female	47	No
2.	Female	47	Yes
3.	Male	53	Yes
4.	Male	67	No
5.	Female	55	Yes
6.	Male	65	Yes
7.	Male	51	Yes
8.	Female	47	Yes
9.	Male	73	Yes
10.	Male	58	Yes
11.	Female	56	Yes
12.	Female	58	Yes
13.	Male	56	No
14.	Male	56	Yes
15.	Male	58	No
16.	Male	40	Yes
17.	Male	53	Yes
18.	Female	58	Yes
19.	Female	51	Yes
20.	Male	48	Yes
21.	Female	60	Yes
22.	Male	55	Yes
23.	Female	55	No
24.	Male	40	Yes
25.	Male	39	Yes
26.	Female	47	Yes
27.	Female	51	Yes
28.	Female	47	No
29.	Male	53	Yes



Patient Number	Gender	Age	Bacterial Growth
30.	Female	58	Yes
31.	Male	50	Yes
32.	Female	56	Yes
33.	Male	56	No
34.	Female	53	Yes
35.	Female	51	Yes
36.	Male	59	No
37.	Female	54	No
38.	Female	61	Yes
39.	Female	64	No

Wound swab culture showed the appearance of microbial drug resistance organisms (MDRO) which is *Escherichia coli*- extended spectrum beta lactamase (ESBL) in 4 patients (13.8%). Our result also found another MDRO which is methicillin resistant *Staphylococcus aureus* (MRSA) in 3 patients (10.4%) (Table 2). In comparison the appearance of Gram-negative bacteria is dominant compare to Gram-positive bacteria (72.4% compare to 27.6%). In case of Gram-negative, the study showed Enterobacteriaceae were seen enormously causing gangrene in DM patients such as *Klebsiella pneumoniae* (3 patients, 10.4%), *Proteus mirabilis* (3 patients, 10.4%).

Table 2. Bacterial profile causing gangrene among DM patient from pus sample

No	Bacteria	Number (Percentage)
Gram-negative bacteria		
1	<i>Escherichia coli</i> (ESBL)	4 (13.8)
2	<i>Klebsiella pneumoniae</i>	3 (10.4)
3	<i>Proteus mirabilis</i>	3 (10.4)
4	<i>Citrobacter freundii</i>	2 (6.9)
5	<i>Citrobacter koseri</i>	2 (6.9)
6	<i>Enterobacter cloacae</i>	2 (6.9)
7	<i>Enterobacter aerogenes</i>	1 (3.5)



No	Bacteria	Number (Percentage)
8	<i>Morganella morganii</i>	1 (3.5)
9	<i>Proteus hauseri</i>	1 (3.5)
10	<i>Shigella</i> sp	1 (3.5)
11	<i>Pseudomonas putida</i>	1 (3.5)
Gram-positive bacteria		
12	<i>Methicillin Resistant Staphylococcus aureus</i> (MRSA)	3 (10.4)
13	<i>Enterococcus faecalis</i>	2 (6.9)
14	<i>Enterococcus avium</i>	1 (3.5)
15	<i>Staphylococcus haemolyticus</i>	1 (3.5)
16	<i>Staphylococcus hominis</i>	1 (3.5)
Total bacterial		29 (100)

Antibiotic resistance test showed that Gram-negative bacteria showed resistant to ampicillin (penicillin type of antibiotic), cefazolin (cephalosporin type of antibiotic) (Table 3). Through antibiotic resistance test, we found *Pseudomonas putida* showed resistance to almost all antibiotic tested except ampicillin and ampicillin sulbactam, meropenem and furantoin (Table 3). In case of *E. coli* ESBL it is shown that beside cephalosporin resistance (cefazolin, ceftriaxone), it was also showed resistance to ampicillin and ciprofloxacin (Table 3). While *E. coli*- ESBL showed susceptibility to carbapenem antibiotics such as ertapenem and meropenem; aminoglikosida such as amikacin; furantoin, amikacin and tigecycline. Other Gram-negative bacteria showed resistance to cephalosporins (cefazolin) and penicillin class (ampicillin) (Table 3). But it showed susceptibility to carbapenem class (ertapenem and meropenem); aminoglikosida class (amikacin and gentamicin); beta lactamase inhibitor class alone or in combination with penicillin class (aztreonam, piperacillin tazobactam); class cephalosporins (ceftazidime, ceftriaxone, cefepime) (Table 4).

Table 3. Antibiotic Resistance Results from Gram-Negative Bacteria Causing Gangrene among DM patients

Antibiotics	AMP	SAM	TZP	KZ	CAZ	CRO	FEP	ATM	ERT A	ME M	AK	GN	CIP	F	SXT	TGC
<i>Escherichia coli</i>	4	2	1	4	2	4	1	3	0	0	0	1	4	0	3	0



(ESBL) n=4 (%)	(100)	(50)	(25)	(100)	(50)	(100)	(25)	(75)	(0)	(0)	(0)	(25)	(100)	(0)	(75)	(0)
<i>Klebsiella pneumoniae</i> n=3 (%)	0 (0)	1 (33)	0 (0)	2(67)	2 (67)	2 (67)	2 (67)	2 (67)	0 (0)	0 (0)	0 (0)	2 (67)	3 (100)	0 (0)	1 (33)	0 (0)
<i>Proteus mirabilis</i> n=3 (%)	2 (67)	1 (33)	1 (33)	3 (100)	1 (33)	1 (33)	1 (33)	2 (67)	0 (0)	0 (0)	0 (0)	1 (33)	1 (33)	3 (100)	2 (67)	2 (67)
<i>Citrobacter freundii</i> n=2 (%)	2 (100)	2 (100)	0 (0)	2 (100)	0 (0)	1 (50)	0 (0)	1 (50)	0 (0)	0 (0)	0 (0)	1 (50)	1 (50)	0 (0)	1 (50)	0 (0)
<i>Citrobacter koseri</i> n=2 (%)	2 (100)	0 (0)	0 (0)	1 (50)	0 (0)	0 (0)	0 (0)	0 (0)	0(0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Enterobacter cloacae</i> n=2 (%)	2 (100)	2 (100)	1 (50)	2 (100)	1 (50)	1 (50)	0 (0)	1 (50)	0 (0)	0 (0)	0 (0)	0 (0)	2 (100)	0 (0)	1 (50)	0 (0)
<i>Enterobacter aerogenes</i> n=1(%)	1 (100)	1 (100)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Proteus hauseri</i> n=1(%)	1 (100)	1 (100)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Morganella morganii</i> n=1(%)	1 (100)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Shigella sp</i> n=1(%)	1 (100)	1 (100)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)	1 (100)	1 (100)	0 (0)
<i>Pseudomonas putida</i> n=1(%)	0 (0)	0 (0)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	0 (0)	1 (100)	1 (100)	1 (100)	0 (0)	1 (100)	1 (100)

AMP, Ampicillin; SAM, Ampicillin Sulbactam; TZP, Piperacillin Tazobactam; KZ, Cefazolin; CAZ, Ceftazidime; CRO, Ceftriaxone; FEP, Cefepim; ATM, Azteronam; ERTA, Ertapenem; MEM, Meropenem; AK, Amikacin; GN, Gentamicin; CIP, Ciprofloxacin; F, Nitrofurantoin; SXT, Trimethoprim/sulfamethoxazole; TGC, Tigecycline.

Table 4. Antibiotic Susceptibility Results from Gram-Negative Bacteria Causing Gangrene among DM patient

Antibiotics	AMP	SAM	TZP	KZ	CAZ	CRO	FEP	ATM	ERT A	ME M	AK	GN	CIP	F	SXT	TGC
<i>Escherichia coli</i> (ESBL) n=4 (%)	0 (0)	0 (0)	3 (75)	0 (0)	2 (50)	0 (0)	3 (75)	1 (25)	4 (100)	4 (100)	4 (100)	3 (75)	0 (0)	4 (100)	1 (25)	4 (100)
<i>Klebsiella pneumoniae</i> n=3 (%)	3 (100)	1 (33)	3 (100)	0 (0)	1 (33)	1 (33)	1 (33)	1 (33)	3 (100)	3 (100)	3 (100)	1 (33)	0 (0)	0 (0)	2 (67)	0 (0)
<i>Proteus mirabilis</i> n=3 (%)	1 (33)	2 (67)	2 (67)	0 (0)	2 (67)	2 (67)	2 (67)	1 (33)	1 (33)	3 (100)	3 (100)	2 (67)	2 (67)	0 (0)	1 (33)	0 (0)
<i>Citrobacter freundii</i> n=2 (%)	0 (0)	0 (0)	1 (50)	0 (0)	1 (50)	1 (50)	2 (100)	0 (0)	2 (100)	2 (100)	2 (100)	1 (50)	1 (50)	1 (50)	1 (50)	2 (100)
<i>Citrobacter koseri</i> n=2 (%)	0 (0)	1 (50)	2 (100)	0 (0)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100)	0 (0)	2 (100)	1 (50)
<i>Enterobacter cloacae</i> n=2 (%)	0 (0)	0 (0)	1 (50)	0 (0)	1 (50)	1 (50)	2 (100)	1 (50)	1 (50)	2 (100)	2 (100)	2 (100)	0 (0)	0 (0)	1 (50)	1 (50)
<i>Enterobacter</i>	0	0	1	0	1	1	1	1	1	1	1	1	1	0	1	1



Antibiotics	AMP	SAM	TZP	KZ	CAZ	CRO	FEP	ATM	ERT A	ME M	AK	GN	CIP	F	SXT	TGC
<i>aerogenes</i> n=1(%)	(0)	(0)	(100)	(0)	(100)	(100)	(100)	(100)	(100)	(100)	(100)	(100)	(100)	(0)	(100)	(100)
<i>Proteus hauseri</i> n=1(%)	0 (0)	0 (0)	1 (100)	0 (0)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	0 (0)	1 (100)	0 (0)
<i>Morganella morganii</i> n=1(%)	0 (0)	0 (0)	1 (100)	0 (0)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	0 (0)	1 (100)	0 (0)
<i>Shigella</i> sp n=1(%)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)	1 (100)	1 (100)	1 (100)	0 (0)	1 (100)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Pseudomonas putida</i> n=1(%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

AMP, Ampicillin; SAM, Ampicillin Sulbactam; TZP, Piperacillin Tazobactam; KZ, Cefazolin; CAZ, Ceftazidime; CRO, Ceftriaxone; FEP, Cefepim; ATM, Azteronam; ERTA, Ertapenem; MEM, Meropenem; AK, Amikacin; GN, Gentamicin; CIP, Ciprofloxacin; F, Nitrofurantoin; SXT, Trimethoprim/sulfamethoxazole; TGC, Tigecycline.

The results of antibiotic resistance test of Gram-positive bacteria showed resistant to tetracyclin and ciprofloxacin. Apart from beta lactam antibiotics, MRSA showed resistance to aminoglycosides class (gentamicin), tetracycline, fluoroquinolone class (moxifloxacin, levofloxacin, ciprofloxacin), lincomycin class (clindamycin) and macrolides class (clindamycin) (Table 5). MRSA showed susceptibility to tigecycline, linezolid, vancomycin and furantoin. Others Gram-positive bacteria showed susceptible to linezolid, vancomycin, tigecycline, ampicillin (Table 6). While other Gram-positive bacteria showed resistance to tetracycline and showed susceptibility to linezolid and vancomycin (Table 5 and 6).

Antibiotics	AMP	OXA	BEN	GN	TGC	SXT	TE	MXF	LEV	CIP	CC	LZD	VA	E	F	Rif
<i>Methicillin Resistant Staphylococcus aureus</i> (MRSA) n=3 (%)	0 (0)	3 (100)	0 (0)	3 (100)	0 (0)	1 (33)	3 (100)	3 (100)	3 (100)	3 (100)	3 (100)	0 (0)	0 (0)	3 (100)	0 (0)	2 (67)
<i>Enterococcus faecalis</i> n=2 (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (50)	0 (0)	0 (0)

<i>Enterococcus</i>	0	0	0	1	0	0	1	0	0	1	0	0	0	0	1	0
<i>avium</i> n=1 (%)	(0)	(0)	(0)	(100)	(0)	(0)	(100)	(0)	(0)	(100)	(0)	(0)	(0)	(0)	(100)	(0)
<i>Staphylococcus</i>	0	1	0	0	0	0	1	0	1	1	0	0	0	0	0	0
<i>haemolyticus</i> n=1 (%)	(0)	(100)	(0)	(0)	(0)	(0)	(100)	(0)	(100)	(100)	(0)	(0)	(0)	(0)	(0)	(0)
<i>Staphylococcus</i>	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
<i>hominis</i> n=1 (%)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Table 5. Antibiotic Resistance Results from Gram-Positive Bacteria Causing Gangrene among DM patient

Antibiotics	AMP	OXA	BEN	GN	TGC	SXT	TE	MXF	LEV	CIP	CC	LZD	VA	E	F	Rif
<i>Methicillin</i>																
<i>Enterococcus</i>	2	0	0	0	2	0	0	0	2	2	0	2	2	0	1	0
<i>faecalis</i> n=2 (%)	(100)	(0)	(0)	(0)	(100)	(0)	(0)	(0)	(100)	(100)	(0)	(100)	(100)	(0)	(50)	(0)
<i>Enterococcus</i>	1	0	0	0	1	0	0	0	0	0	0	1	1	0	0	0
<i>avium</i> n=1 (%)	(100)	(0)	(0)	(0)	(100)	(0)	(0)	(0)	(0)	(0)	(0)	(100)	(100)	(0)	(0)	(0)
<i>Staphylococcus</i>	0	0	1	1	0	1	0	0	0	0	1	1	1	1	0	1
<i>haemolyticus</i> n=1 (%)	(0)	(0)	(100)	(100)	(0)	(100)	(0)	(0)	(0)	(0)	(100)	(100)	(100)	(100)	(0)	(100)
<i>Staphylococcus</i>	0	0	0	1	0	1	1	1	1	1	0	1	0	1	1	0
<i>hominis</i> n=1 (%)	(0)	(0)	(0)	(100)	(0)	(100)	(100)	(100)	(100)	(100)	(0)	(100)	(0)	(100)	(100)	(0)

Table 6. Antibiotic Susceptibility Results from Gram-Positive Bacteria Causing Gangrene among DM Patients

DISCUSSION

Demographic information of DM patient reveals that in term of gender there is no different in probability of DM patient to develop gangrene. While in term of age, DM patients in group of 45-59 years old showing high probability of developing gangrene. This study also in accordance with other studies by Tong *et al* in 2020 that stated DFU (Diabetic Foot Ulcers) is common in middle-aged patients. Also study conducted in Saudi Arabia that showed > 45 years of age can poses a threat for developing DFU (Al-Rubeaan *et al.*, 2015; AlSadrah, 2019). Our study demonstrated that middle-aged patients with DFUs had worse glycemic control, made worse lifestyle decisions like smoking and drinking, had more severe ulcers, and were more likely to have microangiopathy problems. However, these individuals subsequently recovered more quickly and were at a lower risk of death and significant amputation (Tong *et al.*, 2020).

Our result showed that bacterial found in pus culture dominated by Gram-negative bacteria. With *E. coli* ESBL, MRSA, *Klebsiella pneumoniae*, *Proteus mirabilis* being the most common bacteria causing



gangrene. Gram-negative rods were mostly found in patients with chronic wounds that had already been treated. Beginning in the late 1970s, studies showed that aerobic Gram-positive cocci, particularly *Staphylococcus aureus*, were the most common pathogens in DFIs, frequently as monomicrobial infections. Aerobic DFIs brought on by multidrug-resistant organisms, including extended-spectrum beta-lactamase-producing Gram-negative rods (Varaiya *et al.*, 2008) or methicillin-resistant *S. aureus* (MRSA), have become a significant issue in recent years. The choice of an agent active against that isolate is undoubtedly necessary in the event of an infection with an antibiotic-resistant bacterium, but therapeutic management should remain unchanged (Uckay *et al.*, 2012).

When we adding the number of *E. coli* ESBL and MRSA we found that 24 % cases were causing by Multidrug-resistant bacterial infection. Another factor contributing to the appearance of MDRO in other study by Dubsky *et al* in 2013 were because of long term poor glucose control in DM patient (Dubsky *et al.*, 2013). By reducing the therapeutic efficacy of antibiotic therapy, MDRO infection in diabetic foot ulcers makes treatment more difficult and may even result in fatalities or amputations (Agbi *et al.*, 2017; Yan *et al.*, 2022). The risk factors of drug-resistant negative bacilli in patients should be assessed in the development of the initial anti-infective treatment regimen in clinical practice due to the increased resistance rate of *E. coli* ESBL among Gram-negative bacteria. Another study also noted that the appearance of MDRO might be related to the patients with serious illness admitted to our hospital as a tertiary care hospital and the more complex history of antibacterial drug use (Yan *et al.*, 2022).

Systemic antibiotic therapy is required for patients with poor systemic resistance, which typically coexists with bacteremia or sepsis. As a result, it's crucial to perform a thorough evaluation of each patient with diabetic foot ulcers, keep an eye on the severity of the infection and any changes in the pathogenic bacteria, and administer anti-infective therapy in a consistent manner (Tang, 2019). The majority of diabetic foot infections (DFIs) require systemic antibiotic therapy, with empirical selection being the norm at first. Even though there are numerous antibiotics available, it is unclear which one is best for treating DFIs. Antibiotic susceptibility that Gram-negative bacteria (wild type and MDRO) showed susceptibility to meropenem class, aminoglikosida class and beta lactamase inhibitor antibiotic. While for Gram-negative bacteria without MDRO, cephalosporin, beta lactamase antibiotics still susceptible in this study. In case of Gram-positive bacteria, it showed susceptibility to tigecycline, linezolid, vancomycin. Other studies suggested that ertapenem with or without vancomycin also tigecycline can be used to treat DFI infection (Olid *et al.*, 2015). Study by Du *et al* in 2022 also showed that Gram-positive bacteria were susceptible to linezolid, vancomycin, teicoplanin (Du *et al.*, 2022).



CONCLUSION

The gangrene or diabetic foot infection occur in the middle age group (45-59 years) old accounted for 76.9%. Pus culture showed *E. coli* ESBL, MRSA, *Klebsiella pneumoniae*, *Proteus mirabilis* as the dominant bacteria found. Gram-negative bacteria were highly sensitive to meropenem class (ertapenem and meropenem, aminoglikosida class (amikacin, gentamicin) and tigecycline class of antibiotics *Ertapenem*, meropenem, amikacin, gentamicin, piperacillin tazobactam. While Gram-positive bacteria were highly sensitive to tigecycline, linezolid and vancomycin.

ACKNOWLEDGMENTS

The authors wanted to thank East Java Province Government Hospital for giving us the provided research materials. We also wanted to thanked all member of Microbiology department in that hospital for their guidance in helping collecting secondary data. The authors state there is no conflict of interest with the parties involved in this study.

REFERENCES

- Agbi, K.E., Carvalho, M., Phan, H., Tuma, C., 2017. Case Report: Diabetic Foot Ulcer Infection Treated with Topical Compounded Medications. *Intern. J. Pharm. Compd.* Vol. 21(1), Pp. 22-27.
- Akhi, M.T., Ghotaslou, R., Asgharzadeh, M., Varshochi, M., Pirzadeh, T., Memar, M.Y., Bialvaei, A.Z., Sofla, H.S.Y., Alizadeh, N., 2015. Bacterial Etiology and Antibiotic Susceptibility Pattern of Diabetic Foot Infections in Tabriz, Iran. *GMS Hyg. Infect. Control* Vol. 10(2).
- Al-Rubeaan, K., Derwish, M. Al, Ouizi, S., Youssef, A.M., Subhani, S.N., Ibrahim, H.M., Alamri, B.N., 2015. Diabetic Foot Complications and Their Risk Factors from A Large Retrospective Cohort Study. *PLoS One* Vol.10(5), Pp. e0124446.
- Alhubail, A., Sewify, M., Messenger, G., Masoetsa, R., Hussain, I., Nair, S., Tiss, A., 2020. Microbiological Profile of Diabetic Foot Ulcers in Kuwait. *PLoS One* Vol. 15(12), Pp. e0244306.
- AlSadrah, S.A., 2019. Impaired Quality of Life and Diabetic Foot Disease in Saudi Patients with Type 2 Diabetes: A Cross-Sectional Analysis. *SAGE Open Med.* Vol.7, Pp. 2050312119832092.
- Apelqvist, J., Elgzyr, T., Larsson, J., Londahl, M., Nyberg, P., Thorne, J., 2011. Factors Related to Outcome of Neuroischemic/Ischemic Foot Ulcer in Diabetic Patients. *J. Vasc. Surg.* Vol. 53(6), Pp.1582-8.e2.



- Belefquih, B., Frikh, M., Benlahlou, Y., Maleh, A., Jadid, L., Bssaibis, F., Ghazouani, M., Chagar, B., Lamsaouri, J., Lemnouer, A., Elouennass, M., 2016. Diabetic Foot Infection in Morocco: Microbiological Profile. *Wounds* Vol. 28(3), Pp. 89-98.
- Chen, Y., Ding, H., Wu, H., Chen, H.-L., 2017. The Relationship Between Osteomyelitis Complication and Drug-Resistant Infection Risk in Diabetic Foot Ulcer: A Meta-analysis. *Int. J. Low. Extrem. Wounds* Vol. 16(3), Pp. 183-190.
- Du, F., Ma, J., Gong, H., Bista, R., Zha, P., Ren, Y., Gao, Y., Chen, D., Ran, X., Wang, C., 2022. Microbial Infection and Antibiotic Susceptibility of Diabetic Foot Ulcer in China: Literature Review. *Front Endocrinol* Vol.19(13), Pp. 881659.
- Dubsky, M., Jirkovska, A., Bem, R., Skibova, V.F.J., Schaper, N.C., Lipsky, B.A., 2013. Risk Factors for Recurrence of Diabetic Foot Ulcers: Prospective Follow-Up Analysis in The Eurodiale Subgroup. *Intern. Wound J.* Vol. 10(5), Pp. 555-561.
- Gershater, M.A., Londahl, M., Nyberg, P., Larsson, J., Thorne, J., Eneroth, M., Apelqvist, J., 2009. Complexity of Factors Related to Outcome of Neuropathic and Neuroischaemic/Ischaemic Diabetic Foot Ulcers: A Cohort Study. *Diabetologia* Vol. 52(3), Pp. 398-407.
- Heravi, F.S., Zakrzewski, M., Vickery, K., Armstrong, D.G., Hu, H., 2019. Bacterial Diversity of Diabetic Foot Ulcers: Current Status and Future Perspectives. *J. Clin. Med.* Vol. 8(11), Pp. 1935.
- International Diabetes Federation (IDF), 2019. *IDF Diabetes Atlas*, 9 th. ed. International Diabetes Federation (IDF).
- Johannesson, A., Larsson, G.-U., Ramstrand, N., Turkiewicz, A., Wirrh, A.-B., Atroshi, I., 2009. Incidence of Lower-Limb Amputation in The Diabetic and Nondiabetic General Population: A 10-year Population-Based Cohort Study of Initial Unilateral and Contralateral Amputations and Contralateral Amputations and Reamputations. *Diabetes Care* Vol. 32(2), Pp. 275-280.
- Kaur, M., Dhillon, M., Angrup, A., Rangasamy, K., 2022. Polymicrobial Infection Presenting as Non-Clostridial Gas Gangrene in A Non-Diabetic Trauma Patient. *Interantional J. Burn. Trauma* Vol. 12(5), Pp. 194–203.
- Olid, A.S., Ivan Sola, L.A.B.-N., Gianneo, O.D., Cosp, X.B., Lipsky, B.A., 2015. Systemic Antibiotics for Treating Diabetic Foot Infections. *Cochrane Database Syst. Rev.* Vol. 4(9), Pp. CD009061.
- Saltoglu, N., Ergonul, O., Tulek, N., Yemisen, M., Kadanali, A., Karagoz, G., Batirel, A., Ak, O., Sonmezer, C., Eraksoy, H., Cagatay, A., Surme, S., Nemli, S.A., Demirdal, T., Coskun, O.,



- Ozturk, D., Ceran, N., Pehlivanoglu, F., Sengoz, G., Aslan, T., Akkoyunlu, Y., Oncul, O., Ay, H., Mulazımoglu, L., Erturk, B., Yilmaz, F., Yoruk, G., Uzun, N., Simsek, F., Yildirmak, T., Yaşar, K.K., Sonmezoglu, M., Kucukardali, Y., Tuna, N., Karabay, O., Ozgunes, N., Sargin, F., 2018. Influence of Multidrug Resistant Organisms on The Outcome of Diabetic Foot Infection. *Int. J. Infect. Dis.* Vol. 70, Pp. 10-14.
- Schaper, N.C., Netten, J.J. Van, Apelqvist, J., Lipsky, B.A., Bakker, K., Foot, I.W.G. on the D., 2016. Prevention and Management of Foot Problems in Diabetes: A Summary Guidance for Daily Practice 2015, Based on The IWGDF Guidance Documents. *Diabetes. Metab. Res. Rev.* Vol 32(Suppl. 1), Pp. 7-15.
- Spreen, M.I., Gremmels, H., Teraa, M., Sprengers, R.W., Verhaar, M.C., Eps, R.G.S. van, Vries, J.-P.P.M. de, Mali, W.P.T.M., Overhagen, H. van, PADI, Groups, J.S., 2016. Diabetes is Associated with Decreased Limb Survival in Patients with Critical Limb Ischemia: Pooled Data from Two Randomized Controlled Trials. *Diabetes Care* Vol. 39(11), Pp. 2058-2064.
- Tang, Z.Y., 2019. The Comprehension to The Part of Diabetic Foot Infection. In: *Chinese Guideline on Prevention and Management of Diabetic Foot.* *World Clini Drugs.* Vol. 40(9). Pp. 599-602.
- Tong, T., Yang, C., Tian, W., Liu, Z., Liu, B., Cheng, J., Cheng, Q., Zhou, B., 2020. Phenotypes and Outcomes in Middle-Aged Patients with Diabetic Foot Ulcers: A Retrospective Cohort Study. *J. Foot Ankle Res.* Vol. 24.
- Uckay, I., Lubbeke, A., Harbarth, S., Emonet, S., Tovmirzaeva, L., Agostinho, A., Longtin, Y., Peter, R., Hoffmeyer, P., Pittet, D., 2012. Low Risk Despite High Endemicity of Methicillin-Resistant *Staphylococcus aureus* Infections Following Elective Total Joint Arthroplasty: A 12-Year Experience. *Ann. Med.* Vol. 44(4), Pp. 360-368.
- Varaiya, A.Y., Dogra, J.D., Kulkarni, M.H., Bhalekar, P.N., 2008. Extended-Spectrum Beta-Lactamase-Producing *Escherichia coli* and *Klebsiella pneumoniae* in Diabetic Foot Infections. *Indian J. Pathol. Microbiololgy* Vol. 51(3), Pp. 370-372.
- Williams, D.T., Hilton, J.R., Harding, K.G., 2004. Diagnosing foot infection in diabetes. *Clin. Infect. Dis.* An Off. Publ. Infect. Dis. Soc. Am. United States Vol. 1(Suppl. 39), Pp. S83-6.
- Yan, X., Song, J., Zhang, L., Li, X., 2022. Analysis of Risk Factors for Multidrug-Resistant Organisms in Diabetic Foot Infection. *BMC Endocr. Disord.* Vol. 46.

BUKTI KORESPONDENSI
ARTIKEL JURNAL NASIONAL SINTA 2

Judul artikel: Bacterial Profile and Antibiotic Susceptibility Test among Diabetes Mellitus Patients with Gangrene in Surabaya

Jurnal : Journal of Vocational Health Studies, 7 (No. 3)

Author : Imro'atul Qona'ah, 'Aliyah Siti Sundari, Ratna Wahyuni, Dwi Wahyu Indriati

No	Perihal	Tanggal
5	Bukti pengiriman revisi II	22 Agustus 2023

The screenshot shows the submission interface for the Journal of Vocational Health Studies. At the top, there is a dark blue header with the journal name, a notification bell icon, and a user profile icon. Below the header, a navigation bar shows 'Round 1' and 'Round 2', with 'Round 2' being the active tab. The main content area is divided into three sections: 'Round 2 Status' with the message 'Submission accepted.', 'Reviewer's Attachments' with a search button and 'No Files' below it, and 'Revisions' with search and upload file buttons. A single revision entry is listed with a document icon, ID '235394', title 'Revisi-22082023-Ibu Qanaah Bacterial profile and antibiotic.docx', date 'August 22, 2023', and type 'Article Text'.

BUKTI KORESPONDENSI
ARTIKEL JURNAL NASIONAL SINTA 2

Judul artikel: Bacterial Profile and Antibiotic Susceptibility Test among Diabetes Mellitus Patients with Gangrene in Surabaya

Jurnal : Journal of Vocational Health Studies, 7 (No. 3)

Author : Imro'atul Qona'ah, 'Aliyah Siti Sundari, Ratna Wahyuni, Dwi Wahyu Indriati

No	Perihal	Tanggal
6	Bukti penerimaan artikel	24 Agustus 2023

